

No: 24/2025/CV-MP

Hanoi, July 01, 2025

INFORMATION DISCLOSURE

To: - State Securities Commission;

- Hanoi Stock Exchange

1. Company Name: **MEDIPLANTEX NATIONAL PHARMACEUTICAL
JOINT STOCK COMPANY**

Stock Code: MED

Address: No. 358, Giai Phong Road, Hoang Liet Ward, Thanh Xuan District, Ha
Noi City.

Phone: 024.3864 3363

Fax: 024.3864 1584

Email: info@mediplantex.com

Type of information disclosure: ☐ Periodic ☒ Extraordinary ☐ As required

2. Information Disclosure Contents:

- Minutes and Resolution of 2025 Annual General Meeting of Shareholders
- 2025 Annual General Meeting of Shareholders' Documents

3. This information was published on the company's website on July 01, 2025 at
the link: <http://www.mediplantex.com/vi/thong-tin-co-dong.html>.

We hereby commit that the information published above is accurate and are fully
legally responsible for the content of the published information./.

**MEDIPLANTEX NATIONAL PHARMACEUTICAL
JOINT STOCK COMPANY**



Mai Nhat Thanh



AGENDA OF THE 2025 ANNUAL GENERAL MEETING OF SHAREHOLDERS MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY

Time: 8:30 AM, Monday, June 30, 2025.

Venue: T99 Guest House of the Capital Military Zone – No. 99 Le Duan Street, Cua Nam Ward, Hoan Kiem District, Hanoi.

AGENDA Time	Detailed Agenda	Execution
8:00 AM - 8:30 AM	Reception of shareholders and delegates attending the 2025 Annual General Meeting of Shareholders	The Organizing Committee of the General Meeting
	Verification of delegate credentials and distribution of documents	The Delegate Credential Verification Committee
8:30 AM - 9:15 AM	Opening of the meeting and introduction of delegates	The Organizing Committee of the General Meeting
	Report on the verification of shareholder credentials	
	Approval of the General Meeting's agenda	
	Approval of the working regulations and voting at the General Meeting	
	Approval of the Presidium of the General Meeting	
	Approval of the Secretariat and the Vote Counting Committee	
Part 1: 9:15 AM - 10:15 AM Reports & Proposals	- Report of the Board of Directors on the Operational Results for 2024 and the Orientation and Tasks of the Board of Directors for 2025.	Representative of the Board of Directors
	- Report of the Board of Management on the 2024 business and production results and the implementation plan for 2025.	Representative of the Board of Management
	- Report of the Board of Supervisors on its 2024 activities and supervisory work, along with the proposed plan for 2025.	Representative of the Board of Supervisors
	- Proposal for the approval of the audited financial statements for 2024;	Representative of the Board of Directors



AGENDA Time	Detailed Agenda	Execution
	- Proposal for the selection of an independent auditing firm for the 2025 financial statements;	Representative of the Board of Supervisors
	- Proposal for the approval of the profit distribution plan and dividend payout ratio for 2024, and the proposed profit distribution plan and dividend payout ratio for 2025;	Representative of the Board of Directors
	- Proposal for the approval of remuneration for the Board of Directors and the Board of Supervisors for 2025;	Representative of the Board of Directors
	- Approval of the Election for the Additional Member of the Board of Directors for the 2024–2029 Term	Representative of the Board of Directors
	- Other matters within the authority of the General Meeting of Shareholders.	Representative of the Board of Directors
10:15 AM - 10:30 AM	Discussion of the reports and proposals	Chairperson of the General Meeting
10:30 AM - 10:45 AM	Conduct voting on the matters submitted to the General Meeting of Shareholders and elect an additional member to the Board of Directors for the 2024–2029 term	
10:45 AM - 11:00 AM	Break	
11:00 AM - 11:10 AM	Announcement of the voting and election results at the General Meeting of Shareholders	Ballot Counting Committee
11:10 AM - 11:20 AM	Presentation of the draft Minutes and Resolutions of the Meeting	Secretary Committee
11:20 AM - 11:30 AM	Approval of the Minutes and Resolutions of the Meeting	Chairperson of the General Meeting
	Conclusion and declaration of the Meeting's closure	

Hanoi, June 30, 2025

DECISION

**Regarding the Establishment of the Shareholder Eligibility Verification Committee
for the 2025 Annual General Meeting of Shareholders**

**THE BOARD OF DIRECTORS OF MEDIPLANTEX NATIONAL
PHARMACEUTICAL JOINT STOCK COMPANY**

- Pursuant to the Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam, Legislature XIV, on June 17, 2020, and effective as of January 1, 2021;

- Pursuant to the Charter on the organization and operation of Mediplantex National Pharmaceutical Joint Stock Company, as amended and supplemented for the 12th time on June 26, 2024;

- Based on the proposal of the General Director of the Company;

HEREBY DECIDES

Article 1. To establish the Shareholder Eligibility Verification Committee to serve the 2025 Annual General Meeting of Shareholders of Mediplantex National Pharmaceutical Joint Stock Company, comprising the following members:

1. Ms. **Bui Thi Tuyet Lan** – Head of the Committee
2. Ms. **Nguyen Thanh Hang** – Member
3. Ms. **Nguyen Thi Hoang Yen** – Member

The Shareholder Eligibility Verification Committee shall automatically dissolve upon completion of its assigned duties.

Article 2. The Committee is tasked with verifying the eligibility of shareholders attending the 2025 Annual General Meeting of Shareholders in accordance with applicable laws and the Company's Charter.

Article 3. This Decision takes effect from the date of signing. The General Director of Mediplantex National Pharmaceutical Joint Stock Company, the Head of the Organizing Committee of the 2025 Annual General Meeting of Shareholders, and the individuals named in Article 1 shall be responsible for implementing this Decision.

Recipients:

- BOD;
- As stated in Article 3;
- Archived: Office.

ON BEHALF OF THE BOARD OF DIRECTORS



Thai Khắc Minh

No.: 01/2025/TTr – HDQT

Hanoi, June 30, 2025

PROPOSAL

**Regarding the Approval of the Presidium and Secretariat
for the 2025 Annual General Meeting of Shareholders**

To: The General Meeting of Shareholders

Mediplantex National Pharmaceutical Joint Stock Company

To facilitate the administration, recording of meeting contents, and vote counting at the General Meeting of Shareholders, the Board of Directors of Mediplantex National Pharmaceutical Joint Stock Company respectfully proposes to the General Meeting for approval the list of the Presidium and Secretariat for the 2025 Annual General Meeting of Shareholders, as follows::

1. List of Presidium:

- Mr. **Thai Khac Minh** – Chairperson
- Mr. **Tran Nguyen Hoang An** – Member
- Mr. **Mai Nhat Thanh** – Member

2. List of Secretariat:

- Ms. **Chu Huyen Trang** – Head of the Secretariat
- Mr. **Nguyen Dinh Thanh** – Member

Respectfully proposes to the General Meeting of Shareholders for consideration and approval./.

Recipients:

- As above;
- BOD, BOS;
- Archived: Office, BOD Office.

**ON BEHALF OF THE BOARD OF
DIRECTORS**



Thai Khac Minh

**MEDIPLANTEX NATIONAL
PHARMACEUTICAL JSC**

SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

No.: 02/TTr–HDQT

Hanoi, June 30, 2025

PROPOSAL

**Regarding the Approval of the Vote Counting Committee
for the 2025 Annual General Meeting of Shareholders**

To: The General Meeting of Shareholders

of Mediplantex National Pharmaceutical Joint Stock Company

In order to carry out the counting of voting ballots and election ballots at the General Meeting of Shareholders, the Board of Directors of Mediplantex National Pharmaceutical Joint Stock Company respectfully proposes to the General Meeting of Shareholders for approval the list of members of the Vote Counting Committee for the 2025 Annual General Meeting of Shareholders as follows:

List of Vote Counting Committee Members:

1. Ms. **Ha Thi Bich Hanh** – Head of the Committee
2. Ms. **Duong Thi Minh Nguyet** – Member
3. Ms. **Nguyen Thi Xiem** – Member

Respectfully proposes to the General Meeting of Shareholders for consideration and approval./..

Recipients:

- As stated above;
- BOD, BOS;
- Archived: Office, BOD Office.

**ON BEHALF OF THE BOARD OF
DIRECTORS**



Thai Khắc Minh

Hanoi, June 30, 2025

WORKING AND VOTING REGULATIONS
OF THE 2025 ANNUAL GENERAL MEETING OF SHAREHOLDERS
MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY

Pursuant to:

- *The Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020, as amended and supplemented by Law No. 03/2022/QH15 passed by the National Assembly on January 11, 2022, and its guiding documents;*
- *The Law on Securities No. 54/2019/QH14 passed by the National Assembly of the Socialist Republic of Vietnam on November 26, 2019, as amended and supplemented by Law No. 56/2024/QH15 passed by the National Assembly on November 29, 2024, and its guiding documents;*
- *The Charter on Organization and Operation issued together with Resolution of the General Meeting of Shareholders No. 01/2024/NQ-GMS/MED dated June 26, 2024 of Mediplantex National Pharmaceutical Joint Stock Company;*
- *The Internal Regulations on Corporate Governance issued together with Resolution of the General Meeting of Shareholders No. 01/2024/NQ-GMS/MED dated June 26, 2024 of Mediplantex National Pharmaceutical Joint Stock Company;*
- *Resolution of the Board of Directors No. 04/2025/NQ-BOD dated May 09, 2025 of the Board of Directors of Mediplantex National Pharmaceutical Joint Stock Company.*

The 2025 Annual General Meeting of Shareholders of Mediplantex National Pharmaceutical Joint Stock Company (“MED” or the “Company”) shall be convened and conducted in accordance with the following Working and Voting Regulations:

Article 1. Purpose

- To ensure that the procedures, principles of conduct, and voting at the Annual General Meeting of Shareholders of Mediplantex National Pharmaceutical Joint Stock Company are carried out in accordance with regulations and in a successful and orderly manner.
- To ensure that the resolutions of the General Meeting of Shareholders reflect the unified



will of the General Meeting, safeguard the legitimate rights and interests of shareholders, and comply with applicable laws.

Article 2. Scope of Regulation and Subjects of Application

- **Scope of Regulation:** These Regulations shall apply to the organization of the 2025 Annual General Meeting of Shareholders of Mediplantex National Pharmaceutical Joint Stock Company.
- **Subjects of Application:** All delegates and authorized representatives attending the MED Annual General Meeting of Shareholders must comply with the provisions set forth in these Regulations, the Company's Charter, and the prevailing laws and regulations.

Article 3. Conditions for Convening the General Meeting of Shareholders *(Pursuant to the Company's Charter)*

- The General Meeting of Shareholders (GMS) shall be convened when the attending shareholders represent more than 50% of the total voting shares.
- In the event that the required number of shareholders is not present within thirty (30) minutes from the scheduled opening time of the meeting, a second meeting invitation must be issued within thirty (30) days from the intended date of the first GMS. The reconvened GMS shall only be conducted if the attending shareholders and authorized representatives represent at least 33% of the total voting shares.
- If the second meeting cannot be held due to the absence of the required number of attendees within thirty (30) minutes from the scheduled start, a third meeting invitation must be issued within twenty (20) days from the intended date of the second GMS. In this case, the GMS shall be convened regardless of the number of shareholders or authorized representatives in attendance and shall be deemed valid, with the authority to decide on all matters originally proposed for approval at the first GMS.

Article 4. Delegates Attending the General Meeting of Shareholders

1. All shareholders of MED holding voting shares (according to the shareholder list as of the record date: May 29, 2025) have the right to attend or authorize their representative to attend the General Meeting of Shareholders. In the case of individual shareholders, authorization may only be granted to one other individual. In the case of an organizational shareholder with more than one authorized representative attending the meeting as prescribed by law, the number of shares and voting rights assigned to each representative must be clearly specified. An authorized representative who has received power of attorney to attend the meeting is not permitted to further authorize another person to attend on their behalf.

2. Authorization for an individual or organization to represent and attend the General Meeting of Shareholders must be made in writing. The power of attorney must be prepared in accordance with civil law and must clearly state the name of the authorizing shareholder; the name of the individual or organization authorized; the number of shares authorized; the content and scope of authorization; the duration of authorization; and must be signed by both the authorizing party and the authorized party. The authorized individual or organization must submit the original valid power of attorney to the Company before completing registration procedures for attending the meeting.
3. Shareholders and/or authorized representatives hereinafter referred to as "Delegates" must be present at the meeting venue on time and complete the registration procedures with the Organizing Committee of the Meeting. Upon arrival, Delegates must bring lawful identification documents as prescribed in the Notice of the General Meeting to confirm their delegate status.
4. During registration, the Company shall issue each Delegate a voting card and voting and election ballots (if applicable), on which will be recorded the registration number, full name of the shareholder or authorized representative, and the number of votes or election ballots belonging to that shareholder or authorized representative.
5. During the General Meeting of Shareholders, Delegates must comply with the following regulations:
 - a. Be punctual, wear formal attire, comply with security checks (if any), and present identification documents as required by the Meeting Organizing Committee;
 - b. Receive the meeting dossiers and materials at the delegate reception desk;
 - c. Shareholders or authorized representatives arriving after the meeting has commenced may still register and participate in voting immediately after registration. The Chairperson shall not suspend the meeting for late registrants; in such cases, the validity of votes already conducted shall not be affected;
 - d. Keep mobile phones on silent mode or turned off; any necessary calls should be taken outside the meeting room;
 - e. Comply with regulations issued by the Organizing Committee and the Chairperson of the Meeting;
 - f. The Board of Directors may require shareholders or authorized representatives attending the General Meeting to undergo security inspections or other security measures deemed appropriate by the Board of Directors;
 - g. If any shareholder or authorized representative refuses to comply with security checks or

measures mentioned above, the Board of Directors, after careful consideration, may refuse or remove such shareholder or representative from the Meeting.

Article 5. Presidium

1. The Presidium shall consist of 03 members, including 01 Chairperson and 02 members. The Chairman of the Board of Directors shall serve as the Chairperson of the Presidium and shall be Chairperson of the 2025 Annual General Meeting of Shareholders of MED.
2. In case the Chairperson is absent or temporarily unable to perform duties, the remaining members shall elect one among themselves to act as the Chairperson of the meeting according to the majority rule. In the event that no Chairperson is elected, the Head of the Board of Supervisors shall preside over the process for the General Meeting of Shareholders to elect a Chairperson of the meeting, and the person who receives the highest number of votes shall act as the Chairperson of the meeting.
3. Duties of the Presidium:
 - a. To preside over the activities of the General Meeting of Shareholders in accordance with the Agenda proposed by the Board of Directors and approved by the General Meeting;
 - b. To guide the Delegates and the Meeting in discussing the matters included in the agenda;
 - c. To present draft resolutions and provide conclusions on necessary issues for the General Meeting to vote on;
 - d. To respond to matters requested by the General Meeting;
 - e. To address any issues arising during the course of the Meeting.

4. Working principles of the Presidium:

The Presidium shall operate on the principles of collectivity, democratic centralism, and decision-making by majority vote..

Article 6. Secretariat of the General Meeting

1. The Secretariat of the General Meeting shall consist of 02 members nominated by the Chairperson (through the Organizing Committee of the General Meeting); it shall be accountable to the Presidium and the General Meeting of Shareholders for the fulfillment of its assigned duties and shall operate under the direction of the Presidium.
2. Duties of the Secretariat:
 - a. Assist the Presidium in verifying the qualifications of the attending delegates (when necessary);

- b. Support the Presidium in announcing draft documents, conclusions, and Resolutions of the General Meeting and in delivering notifications from the Presidium to the Delegates upon request;
- c. Receive and review Discussion Slips and delegates' opinions, and forward them to the Presidium for consideration and decision;
- d. Record fully and accurately the entire proceedings of the General Meeting and all approved or noted matters in the Meeting Minutes;
- e. Prepare the Minutes of the Meeting and draft the Resolution on the matters approved at the General Meeting;
- f. Support the Chairperson in disclosing information related to the General Meeting of Shareholders and in notifying the Delegates in accordance with legal regulations and the Company's Charter.

Article 7. Delegates Eligibility Examination Committee

- 1. The Delegates Eligibility Examination Committee of the General Meeting shall consist of 03 members, including 01 Head and 02 members, established by the Board of Directors and introduced to the General Meeting by the Presidium. The Committee shall be accountable to the Presidium and the General Meeting of Shareholders for the performance of its duties.
- 2. Duties of the Delegates Eligibility Examination Committee:
 - a. The Committee is responsible for verifying the qualifications and attendance status of shareholders participating in the meeting
 - b. The Head of the Committee shall report to the General Meeting of Shareholders on the status of shareholders in attendance. If the meeting has a sufficient number of delegates representing more than 50% of the total voting shares, the MED General Meeting of Shareholders shall be deemed valid and may proceed.

Article 8. Vote Counting Committee

- 1. The Vote Counting Committee of the General Meeting shall consist of 03 members, including 01 Head and 02 members, who are nominated by the Chairperson (through the Meeting Organizing Committee) and approved by the General Meeting.
- 2. Duties of the Vote Counting Committee:
 - a. Disseminate the principles, regulations, and guidelines on the voting procedures;
 - b. Verify and record voting cards, prepare vote counting minutes, announce results; submit the minutes to the Chairperson for approval of voting and election results;
 - c. Promptly notify the Meeting Secretary of the voting results;
 - d. Review and report to the General Meeting any violations of voting regulations or

- complaints regarding the voting results;
- e. Prepare the vote counting minutes and be accountable to the Presidium and the General Meeting of Shareholders in the performance of their duties.

Article 9. Discussion at the General Meeting

1. Principles:

- a. Discussions shall only take place within the prescribed time and within the scope of issues presented in the agenda of the General Meeting of Shareholders;
- b. Delegates wishing to speak must register their topics on the Discussion Sheet and submit it to the Secretariat;
- c. The Secretariat shall organize the Discussion Sheets of the delegates in order of registration and forward them to the Presidium;
- d. Delegates must raise their hand when wishing to speak or debate and may only speak upon approval by the Presidium. Each delegate's speech shall not exceed 5 minutes, and content must be concise and avoid repetition.

2. Response to delegates' opinions:

- a. Based on the delegates' Discussion Sheets, the Chairperson or a member appointed by the Chairperson shall respond to the delegates' opinions;
- b. In cases where time constraints prevent direct responses at the meeting, MED shall provide written answers to the questions after the General Meeting..

Article 10. Voting

1. Principles:

- a. All matters in the agenda and contents of the General Meeting must be openly discussed by the General Meeting of Shareholders and openly voted on either by raising voting cards or by secret ballot using voting slips.
- b. Voting cards and voting slips are printed, sealed with the company's stamp, and directly delivered by MED to delegates at the meeting (attached with the set of documents for attending the General Meeting). Each delegate is issued one voting card and one voting slip. On the voting card and voting slip, the delegate's registration code, full name, number of shares owned and proxy votes authorized to the delegate are clearly indicated.
- c. Forms of voting on matters at the 2025 Annual General Meeting of Shareholders:
 - ***Voting by raising the voting card:*** this form is used to approve matters such as the Meeting agenda; the Working and Voting Regulations at the Meeting; approval of the Vote Counting Committee; approval of the Meeting Minutes, Meeting Resolutions, and other contents at the Meeting (if any);

- *Voting by filling out the voting ballot:* this form is used to approve the contents of proposals submitted to the Meeting, as specified and clearly indicated in each voting ballot sent to each shareholder.

2. Voting Method:

- a. Delegates shall cast their vote as “Agree,” “Disagree,” or “Abstain” on each matter put to a vote at the General Meeting by either raising the Voting Card or marking the corresponding options on the Voting Slip in accordance with the provisions of Clause 2 of this Article.
- b. When voting by raising the Voting Card:
 - The front side of the Voting Card must be held up facing the Presidium.
 - In the event that a delegate does not raise the Voting Card during any of the three voting rounds (“Agree,” “Disagree,” or “Abstain”) on a matter, it shall be deemed as a vote in favor of that matter.
 - In the event that a delegate raises the Voting Card more than once across the three voting rounds (“Agree,” “Disagree,” or “Abstain”) on a matter, the vote for that matter shall be considered invalid.
 - Under this form of voting, members of the Vote Counting Committee/Delegate Eligibility Verification Committee shall mark the delegate code and corresponding number of votes of each shareholder as “Agree,” “Disagree,” “Abstain,” or Invalid.
- c. When voting by filling out the Voting Ballot:
 - For each item, the delegates shall select one of the three options “Agree,” “Disagree,” or “Abstain,” which are pre-printed on the Voting Ballot, by marking “x” or “✓” in the box corresponding to their choice.
 - In the case that a delegate or proxy arrives after the Voting Ballot collection has concluded, such delegate may still register and vote on issues arising after their registration, but shall not be permitted to vote on matters for which voting has already been completed. In this case, the validity of previously conducted votes shall remain unaffected.
 - A voting item shall be deemed invalid if the shareholder or authorized representative does not mark any voting box or marks more than one box for the same item. If a Voting Ballot is otherwise valid but contains one or more invalid voting items, the valid votes on the remaining items shall still be counted in the results for those respective items.
 - Upon completing all voting items of the General Meeting, the delegate shall submit the Voting Ballot into the sealed ballot box provided at the meeting, as instructed by the Vote

Counting Committee. The Voting Ballot must bear the delegate's signature and full name.

3. Valid Voting Ballot:

- a. The Ballot must be based on the pre-printed template issued by the Organizing Committee;
- b. It must not contain any erasures, scratching, alterations, tears, or damage, and must not include any additional voting content beyond what is stipulated for the slip.
- c. It must bear the handwritten signature and full name of the attending delegate.
- d. For each item on the Voting Ballot, the vote is considered valid when the delegate marks only one (01) of the three (03) voting options for that item.

4. Invalid Voting Ballot:

- a. The Ballot is not issued by the Organizing Committee;
- b. The Ballot is not signed and does not contain the full handwritten name of the delegate;
- c. The Ballot does not bear MED's official red seal or contains erasures, scratching, alterations, or any additional markings or content beyond what is stipulated for the voting slip;
- d. The Ballot contains only invalid voting items;
- e. The Ballot is submitted after the ballot box has been unsealed.

5. In the event that a delegate requests to exchange a voting ballot due to it being torn, damaged, or inadvertently marked with additional symbols ("damaged voting slip"), and provided that the delegate has not yet cast the vote into the ballot box and the voting period has not expired, the delegate shall have the right to directly approach the Vote Counting Committee to return the damaged voting ballot in exchange for a new one, in order to safeguard shareholder rights. The Vote Counting Committee shall collect all damaged voting slips and submit them to the Presidium.

6. Approval of Resolutions by the General Meeting of Shareholders:

- a. Pursuant to Clause 1, Article 21 of the Company's Charter, a resolution on the following matters shall be passed if it is approved by shareholders representing **at least 65%** of the total voting rights of all shareholders attending and voting at the General Meeting:
 - Amendments and supplements to the Company's Charter;
 - Types of shares and the total number of shares to be offered;
 - Merger, reorganization, and dissolution of the Company;
 - Decisions on investments or transactions involving the sale of assets with a value equal to or greater than 35% of the total asset value recorded in the most recent audited financial

statements of the Company;

- Changes to business sectors, lines, and fields of operation.
- b. Except for the above-mentioned cases, other resolutions shall be approved when voted in favor by shareholders representing more than 50% of the total voting rights of all shareholders attending and voting at the General Meeting, unless otherwise provided in Clause 1, Article 21 of the Company's Charter and Clauses 3, 4, and 6.

Article 11. Voting for the Additional Election of Members of the Board of Directors (Election):

1. The election of additional members to the Board of Directors for the 2024 – 2029 term shall be conducted by cumulative voting. Accordingly, each shareholder shall have a total number of votes equal to the number of shares they hold multiplied by the number of additional members to be elected to the Board of Directors for the 2024–2029 term. Shareholders may allocate all or part of their total votes to one or more candidates, but the total number of elected candidates must not exceed the number approved by the General Meeting of Shareholders. The elected candidates shall be those who receive the highest number of votes, in descending order, until the number of required members is reached. In the event that two or more candidates receive an equal number of votes for the final seat(s), a re-election shall be conducted among those candidates, or an alternative selection method shall be used based on criteria approved by the General Meeting of Shareholders.
2. Instructions for Completing the Ballot:
 - Each ballot for electing members of the Board of Directors may be used to vote for a maximum number of candidates equal to the number of seats approved by the General Meeting of Shareholders.
 - Each ballot includes two columns: the “Cumulative Voting” column and the “Number of Votes” column. Shareholders shall cast their votes according to the following instructions:
 - Case 1: If the shareholder allocates all votes to a single candidate**
 - + The shareholder shall mark an "X" in the box under the “Cumulative Voting” column corresponding to that candidate.
 - Case 2: If the shareholder chooses not to vote for any candidate**
 - + The shareholder shall leave all fields in both the “Cumulative Voting” and “Number of Votes” columns blank for all candidates, without making any marks or annotations.
 - + The shareholder or the authorized representative of the shareholder must sign and clearly write their full name on the ballot.
3. Validity and Invalidity of Ballots
 - Valid Ballot: A valid ballot must be the official printed form issued by the Organizing Committee, without erasures, alterations, or any additional content beyond the designated

sections. It must bear the signature and clearly printed full name of the attending shareholder or their authorized representative.

- The following ballots shall be considered invalid:
 - + Ballots containing any additional content not specified in the official template;
 - + Ballots filled in using a pencil;
 - + Ballots on which candidate names have been crossed out;
 - + Ballots that are not on the official printed form issued by the Organizing Committee, or that have been erased, altered, or contain added content beyond the ballot's intended format;
 - + Ballots on which the number of candidates selected exceeds the number of Board of Directors members approved by the General Meeting of Shareholders for the 2024–2029 term;
 - + Ballots submitted after the Ballot Counting Committee has unsealed the ballot box;
 - + Ballots that do not contain the signature of the attending shareholder.

Article 12. Minutes and Resolutions of the General Meeting of Shareholders

The minutes of the meeting and the resolutions of the General Meeting of Shareholders must be read aloud and adopted prior to the closing of the General Meeting.

Article 13. Implementation of the Regulations

All delegates and invited participants attending the General Meeting must strictly comply with these Regulations on working procedures and voting, the current rules, internal regulations, corporate governance provisions of the Company, and all relevant legal regulations. Any delegate who violates these Regulations shall, depending on the severity of the violation, be subject to consideration and appropriate measures by the Presidium in accordance with the Company's Charter and the Law on Enterprises.

These Regulations comprise 13 Articles and shall take effect immediately upon approval by the 2025 General Meeting of Shareholders of the Company.

ON BEHALF OF THE BOARD OF DIRECTORS



Thai Khắc Minh

No 01/2025/BC-MED

Hanoi, June 30, 2025

**REPORT OF THE BOARD OF DIRECTORS ON ITS PERFORMANCE IN 2024 AND
THE PROPOSED OPERATIONAL PLAN FOR 2025**

To: The General Meeting of Shareholders
of Mediplantex National Pharmaceutical Joint Stock Company

- Pursuant to the Law on Enterprises No. 59/2020/QH14 dated June 17, 2020, as amended by Law No. 03/2022/QH15 passed by the National Assembly of the Socialist Republic of Vietnam on January 11, 2022;
- Pursuant to the Charter on Organization and Operation of Mediplantex National Pharmaceutical Joint Stock Company;

The Board of Directors for the 2024–2029 term of Mediplantex National Pharmaceutical Joint Stock Company respectfully submits to the Annual General Meeting of Shareholders the Report of the Board of Directors on our performance in 2024 and the proposed operational plan for 2025 with the following main contents:

I. 2024 PERFORMANCE RESULTS

1. Board of Directors Personnel Structure

No.	Member	Position	Date of Commencement/ Termination as BOD Member/ Independent BOD Member	
			Date of appointment	Date of dismissal
1	Tran Hoang Dung	BOD Chairman	26/06/2024	
2	Tran Xuan Dinh	BOD Member	26/06/2024	
3	Tran Nguyen Hoang An	BOD Member	26/06/2024	
4	Nguyen Thi Thuy	BOD Member	26/06/2024	
5	Thai Khac Minh	BOD Independent member	26/06/2024	
6	Doan Thi Hong Thuy	BOD Chairman		26/6/2024



7	Tran Hoang Dung	BOD Vice Chairman		26/6/2024
8	Le Hong Trung	BOD Member		26/6/2024
9	Nguyen Ngoc Tuyen	BOD Member		26/6/2024
10	Nguyen Tien Phong	BOD Member		26/6/2024
11	Nguyen Van Khai	BOD Member		26/6/2024
12	Do Van Tan	BOD Independent member		26/6/2024

The composition of the BOD ensures a balanced structure among executive members, non-executive members, and independent members in accordance with the Company's Charter and the Internal Corporate Governance Regulations.

2. Resolutions/Decisions of the Board of Directors

In 2024, the Board of Directors convened 12 meetings to deliberate and decide on various matters within its functions and authority, resulting in the issuance of 14 resolutions.

All members of the Board of Directors attended the meetings in full, with the participation of the Board of Supervisors.

3. Activities of the Board of Directors

In 2024, the BOD operated in accordance with its functions, duties, and authority as prescribed by the Law on Enterprises, the Company's Charter, and applicable laws. All BOD meetings were organized and conducted in compliance with legal regulations, the Charter, and the Company's internal rules and procedures.

- All BOD members actively participated in meetings and jointly provided timely guidance, contributing to the effective achievement of the targets set by the General Meeting of Shareholders' resolutions.
- 2024 marked the transition between the 2020–2024 and 2024–2029 terms. BOD members regularly exchanged information to implement the Company's strategic objectives and promptly adjust to each development phase.
- Tasks were assigned among BOD members, and Mr. Tran Hoang Dung was elected as Chairman of the BOD.
- Mr. Tran Xuan Dinh was appointed as the General Director.
- The BOD issued internal regulations on financial management, internal expenditure, and debt management to strengthen corporate governance and improve oversight and control over operations, minimizing risks in business activities.

- Cost control was enforced across all departments, with a focus on managing receivables and payables, ensuring credit safety, and reinforcing professional oversight to minimize technical errors in operations.
- All information related to the Company's business activities was disclosed in a timely and transparent manner.

Key Performance Indicators Achieved in 2024

No.	Indicator	Unit	Plan 2024	Actual 2024	% Actual/Plan 2024
I	Industrial Production				
1	Plant cost	VND	278,729,761,000	297,475,347,000	106.7%
	Plant No. 1	VND	70,749,851,000	83,127,899,000	117.5%
	Plant No. 2	VND	207,979,910,000	214,347,448,000	103.1%
2	Production Output of the Two Plants	Product Unit	635,386,000	650,122,000	102.3%
	Plant No. 1	Product Unit	86,413,000	103,395,000	119.7%
	Plant No. 2	Product Unit	548,973,000	546,727,000	99.6%
II	Overall Company Results				
1	Total Revenue	VND	360,724,200,700	443,135,811,734	122.8%
2	Total Cost of goods sold	VND	280,114,838,340	350,574,416,654	125.2%
3	Gross Profit	VND	80,609,362,360	92,561,395,080	114.8%
5	Financial Expenses	VND	7,500,000,000	5,882,463,007	78.4%
7	Selling Expenses	VND	8,800,000,000	7,956,365,486	90.4%
8	General and Administrative Expenses	VND	48,692,066,920	62,411,577,931	128.2%
III	Earning before tax	VND	16,117,295,440	19,418,107,894	120.5%

Indicator	2023	2024	% Change
Total Asset	555,242,708,304	503,755,172,939	-9.27%
Revenue	402,741,168,246	443,135,811,734	10.0%
Operating Profit	15,321,686,437	18,505,896,390	20.8%
Other Profit	(398,621,480)	912,211,504	328.8%
Earning before tax	14,923,064,957	19,418,107,894	30.1%
Net Profit	11,743,892,351	15,246,766,212	29.8%

1. Supervision Results of the Board of Directors over the General Director

The new-term Board of Directors dismissed Mr. Tran Hoang Dung from the position of General Director, appointed Mr. Tran Xuan Dinh as the new General Director, and restructured the Board of Management.

The BOD directed and supervised the operations of the BOM, promptly addressing matters within the BOD's authority.

The BOD's assessment: The BOM performed its assigned duties in accordance with the law, the Company's Charter, resolutions of the General Meeting of Shareholders (GMS), and resolutions/decisions of the BOD, specifically:

- The Board of Management submitted regular reports at BOD meetings and provided ad-hoc reports upon request whenever issues arose under the authority of the BOD or its Chairman, so that timely guidance and solutions could be given to support and facilitate the BOM's operations.
- Successfully organized the 2024 Annual General Meeting of Shareholders on June 26, 2024.
- Effectively implemented the key tasks and solutions in 2024 as directed by the Board of Directors:
- + The Board of Management was fully aware of both the opportunities and challenges, and thus operated the business flexibly. It issued internal regulations and decisions within the authority of the General Director to effectively manage all business activities, resulting in an earning before tax that exceeded the 2024 target by 20.5%.

- + The BOM intensified efforts in debt collection, reducing overall debt levels, especially overdue receivables. Cash flow planning was well-controlled to optimize financial costs and reduce bank interest expenses.
- + The BOM strictly managed production costs and office administration expenses. All procurement and investment activities were conducted in accordance with the Company's internal regulations and applicable laws.

2. Evaluation Results from the Independent Member on the Activities of the Board of Directors

As of December 31, 2024, the Company's BOD included two independent members. These members participated in 100% of the BOD's meetings and written consultations in 2024, and contributed valuable input to the Company's strategic direction and development.

Based on their assessment of the BOD's activities in 2024, the independent members concluded:

- BOD meetings were convened and conducted according to a clear schedule, with well-prepared documentation in accordance with regulations. The BOD operated effectively, making timely and appropriate decisions aligned with the Company's situation and market conditions. Meetings were held regularly, and important matters were thoroughly discussed and resolved by consensus.
- Development strategies, plans, and policies were implemented in line with the orientations approved by the General Meeting of Shareholders.
- The BOD placed strong emphasis on risk management to ensure stable and sustainable operations. Potential risks were identified and assessed carefully, with effective mitigation measures applied.
- The BOD fulfilled its assigned duties with high responsibility and professionalism, in strict compliance with laws, the Company's Charter, and ethical standards in business activities.

3. Remuneration and Salary Payment for the Board of Directors

The salary and remuneration for the Board of Directors were paid in accordance with the resolution of the 2024 Annual General Meeting of Shareholders (*The figures are reflected in the audited 2024 financial statements*).

4. Transactions with Related Parties

No.	Name	Related Party Relationship	NSH No. / Issue Date / Place of Issue	Head Office Address	Transaction Time
-----	------	----------------------------	---------------------------------------	---------------------	------------------

1	An Hy Pharmaceutical Company Limited	Related Party of Mr. Tran Hoang Dung – Chairman of the Board of Directors	Enterprise Registration Certificate No. 0309738339, issued on May 22, 2017 by the Department of Planning and Investment of Ho Chi Minh City	No. 506/15/34, 3/2 Street, Ward 14, District 10, Ho Chi Minh City	2024
2	Northern Medibros Medicine Joint Stock Company	Mr. Le Hong Trung and Mr. Nguyen Tien Phong (dismissed) were members of the Company's Board of Directors.	Enterprise Registration Certificate No. 0107575836, issued on September 25, 2016 by the Department of Planning and Investment of Hanoi City	No. 358 Giai Phong Street, Phuong Liet Ward, Thanh Xuan District, Hanoi City	2024
3	Medibros Central Regional Pharmaceutical Joint Stock Company	Mr. Nguyen Tien Phong (dismissed) was a member of the Company's Board of Directors.	Enterprise Registration Certificate No. 0401696994, issued on September 18, 2015 by the Department of Planning and Investment of Da Nang City	No. 512, 29/03 Street, Hoa Xuan Ward, Cam Le District, Da Nang City	2024

II. ORIENTATION AND OPERATION PLAN FOR 2025

The economic outlook for 2025 remains subject to significant volatility, with ongoing uncertainties related to geopolitical tensions, international tariff policies, and disruptions in global supply chains. Domestically, the pharmaceutical sector continues to face numerous administrative hurdles and regulatory changes that substantially affect production activities and product distribution.

Based on an assessment of current production capacity and market risk factors, the Board of Directors of Mediplantex National Pharmaceutical Joint Stock Company proposes to submit the 2025 Business and Production Plan to the General Meeting of Shareholders as follows:

1. Business Plan for 2025:

No	Indicator	Unit	Amount
I	Industrial Production	Product Unit	513,703,843

1	Plant No.1	Product Unit	87,055,738
2	Plant No.2	Product Unit	426,648,105
II	Total Revenue	VND	299,907,000,113
III	Cost of goods sold	VND	223,094,819,228
IV	Gross Profit	VND	76,812,180,885
V	Selling Expenses	VND	5,009,034,126
	Financial Expenses	VND	3,850,000,000
VI	Administrative Expenses	VND	55,049,459,188
VII	Earning before tax	VND	12,903,687,571

2. Operational Orientation and Solutions:

- In 2025, the Board of Directors will continue holding regular quarterly meetings in accordance with regulations, as well as ad-hoc meetings and written consultations with BOD members to implement the Resolutions of the 2025 Annual General Meeting of Shareholders, address corporate governance matters, and direct the execution of 2025 tasks.
- Strengthen governance over economic targets and corporate management by organizing an efficient operating system and ensuring transparent control over key areas such as timely debt collection, company expenses, and capital utilization.
- Direct the Board of Management to focus on consolidating and expanding production at the Company's plants, based on scientifically and strategically positioning key products.
- Enhance conditions for R&D efforts, focusing on the development of high-value, knowledge-intensive products that offer economic efficiency, gradually replacing and improving strategic products.
- Improve digital management by accelerating digital transformation and applying artificial intelligence across all operational aspects of the Company.

This report presents the Board of Directors' assessment of its performance in 2024 and the proposed operational plan for 2025. The achievements in 2024 have laid a solid foundation for our continued confidence in the sustainable development of Mediplantex National Pharmaceutical Joint Stock Company. On behalf of the Board of Directors, I would like to express my sincere thanks to the Board of Management and all company staff for their constant dedication and efforts toward the growth and success of Mediplantex. We also extend our Report of BOD on its performance in 2024 and the proposed operational plan for 2025

heartfelt appreciation to our valued shareholders, investors, customers, and partners for your unwavering trust and continued support on the journey toward a prosperous and sustainable Mediplantex.

Sincerely!

Recipients:

- BOD
- BOM
- Shareholders
- State Securities Commission
- Archived: Company Secretary



No. 02/2025/BC-MED

Hanoi, June 30, 2025

REPORT OF THE BOARD OF MANAGEMENT ON THE 2024 BUSINESS AND PRODUCTION RESULTS AND THE IMPLEMENTATION PLAN FOR 2025

To: The General Meeting of Shareholders
of Mediplantex National Pharmaceutical Joint Stock Company

In 2024, the global economy continued to face numerous challenges, marked by unpredictable developments and widespread instability. The pharmaceutical sector, in particular, was affected not only by international headwinds but also by certain domestic regulatory barriers, including circulars and decrees, which impacted business operations. In response to these circumstances, Mediplantex set a unified overarching objective, adopted flexible management strategies, and relied on a resilient and committed team of employees, all determined to overcome this challenging period together.

I. BUSINESS PERFORMANCE RESULTS IN 2024:

1. Favorable Factors during the Year:

- A reputable brand and good product quality trusted by partners.
- A leadership team with vision, dedication, and innovative thinking.
- A united, committed workforce with high professional skills.
- Consensus and support from the company's shareholders.

2. Challenges in Implementing the Business and Production Plan:

- Changes in the Drug Administration's regulatory policies caused prolonged delays in the issuance, renewal, and modification of marketing authorizations, exceeding the prescribed timelines. Frequent updates and additions to regulations on drug pricing dossiers required the company to devote significant time to documentation, resulting in a lack of valid registration numbers for production and sales.
- The domestic market for pharmaceuticals and health supplements has not seen significant recovery due to difficulties in implementing policies related to drug bidding in healthcare facilities.
- The organizational structure of the manufacturing plant and intermediary departments remained cumbersome and had not been streamlined. A large workforce involved in production led to high personnel management costs. Amid economic challenges, optimizing labor resources presented a major difficulty in balancing operational efficiency and cost.

- Volatile prices of raw materials, excipients, and packaging materials, along with disrupted supply chains due to price competition, forced the company to continuously seek and qualify alternative suppliers. This impacted production timelines and cost strategy planning.

3. Key Solutions and Core Tasks Implemented During the Year:

- The Board of Management carried out a restructuring to help the company operate more effectively, based on existing foundations of mission, vision, and strategic orientation. The workforce and working processes between units and departments were reorganized to match the company's production model.
- Implemented work plans appropriate to the actual situation and consistently aligned with the 2024 business plan, ensuring conformity with the company's development orientation.
- Strengthened Financial Risk Management:
 - + Enhanced control over accounts receivable to minimize capital encroachment.
 - + Improved capital turnover to optimize financial efficiency.
 - + Prevented the emergence of bad debts and successfully recovered outstanding receivables.
- Improved Operational Efficiency in Production:
 - + Strengthened quality control from raw material inputs to finished product outputs.
 - + Organized efficient production management to prevent waste, reduce material consumption, and allocate labor rationally to lower production costs.
- Market Expansion and Product Diversification
 - + Promoted research and development of new products in line with consumer trends.
 - + Expanded distribution channels and partnered with strategic collaborators to increase market share.

4. Performance Indicators Achieved:

No.	Indicator	Unit	2024 Plan	2024 Actual Performance	% 2024 Actual Performance/ 2024 Plan
I	Industrial Production				
1	Factory Cost	VND	278,729,761,000	297,475,347,000	106.7%
	Plant No. 1	VND	70,749,851,000	83,127,899,000	117.5%
	Plant No. 2	VND	207,979,910,000	214,347,448,000	103.1%
2	Production Output of the Two Plants	Unit of product	635,386,000	650,122,000	102.3%
	Plant No. 1	Unit of product	86,413,000	103,395,000	119.7%
	Plant No. 2	Unit of product	548,973,000	546,727,000	99.6%
II	Company-Wide Summary				

1	Total Revenue	VND	360,724,200,700	443,135,811,734	122.8%
2	Total Cost of Goods Sold	VND	280,114,838,340	350,574,416,654	125.2%
3	Gross Profit	VND	80,609,362,360	92,561,395,080	114.8%
5	Financial Expenses	VND	7,500,000,000	5,882,463,007	78.4%
7	Selling Expenses	VND	8,800,000,000	7,956,365,486	90.4%
8	General and Administrative Expenses	VND	48,692,066,920	62,411,577,931	128.2%
III	Profit Before Tax	VND	16,117,295,440	19,418,107,894	120.5%

- In addition, the Board of Management directed a focused effort on research and development of new products, as well as the formulation of the company's strategic product portfolio, which has yielded the following positive outcomes:

No.	Indicator	Unit	2023	2024
1	New registration numbers granted	Product	18	23
2	Renewal registration numbers granted	Product	28	157
3	Health supplements and cosmetics newly registered	Product	2	09
4	Price declaration dossiers approved	Product	30	10
5	Approved changes, supplements, and updates	Product	76	192 (14 dossiers for manufacturer supplements)
6	Approved changes, supplements, and updates	Product		18
7	Implemented improvements to formulas and production processes	Product	17	05

5. Status of the Investment Project “Pharmaceutical Science and Technology Center and Application-based Pharmaceutical Manufacturing Plant meeting EU-GMP Standards”:

5.1 Content:

- Amendment of the Enterprise Registration Certificate No. 0100108430 issued by the Hanoi Department of Planning and Investment, first issued on April 12, 2005, with the 20th amendment registered on January 3, 2025
- Adjustment of the project scale, specifically the production capacity:

- Increase in production volume of cephalosporin antibiotic tablets/granules/powders (nano products) from 100,000,000 units/year (equivalent to 50 tons/year) to 300,000,000 units/year (equivalent to 150 tons/year); Increase in production volume of cephalosporin antibiotic injections (nano-based products) from 20,000,000 units/year (equivalent to 5 tons/year) to 32,000,000 units/year (equivalent to 8 tons/year).
- Adjustment of total investment capital: Increase in total investment capital by 20% or more, resulting in a change in project investment scale (from VND 724 billion to VND 892 billion).
- Adjustment of implementation schedule:
 - Phase 1:
 - + Commencement of construction, implementation, acceptance, and completion of Office Building, Workshops B and C, and auxiliary works, and putting them into use: Q4/2020 – Q1/2026
 - + Installation of machinery, equipment, and trial operation of Phase 1 workshops: Q1/2026 – Q2/2026
 - + Commissioning and operational launch of Phase 1 facilities: Q3/2026.
 - Phase 2:
 - + Commencement of construction, implementation, acceptance, and completion of Workshop A, Workshop D, and Central Warehouse, and putting them into use: Q4/2025 – Q2/2027.
 - + Installation of machinery, equipment, and trial operation of Phase 2 workshops: Q2/2027 – Q3/2027
 - + Commissioning and operational launch of Phase 2 facilities: Q4/2027.

2. Outcome:

- The Hoa Lac Hi-Tech Park Management Board issued Decision No. 235/QĐ-CNCHL approving the adjustment of the investment policy (initial approval dated July 19, 2019; first amendment on November 27, 2024).

II. BUSINESS OPERATION ORIENTATION FOR 2025

1. Challenges and Difficulties in Implementing the 2025 Plan

The year 2025 is projected to remain challenging across various global economic sectors, with key obstacles as follows:

- Global Geopolitical Instability: Ongoing tensions in several regions (e.g., Europe, the Middle East) continue to disrupt global supply chains, posing significant challenges to the importation of raw materials, pharmaceutical excipients, and packaging essential for production.

- **New Tariff Policies:** Newly implemented trade and tariff regulations by various countries may cause exchange rate volatility, increase import costs, and elevate risks associated with export expansion, thereby impacting the company's international trade strategies.
- **Currency Fluctuations:** Unstable foreign exchange rates, particularly involving the USD and CNY, will likely increase the cost of imported inputs—which represent a significant proportion of product cost—thus putting pressure on profit margins, pricing strategies, and possibly disrupting raw material supply continuity.
- **Regulatory Hurdles in the Pharmaceutical Sector:** Persistent regulatory bottlenecks remain unresolved. Widespread inspections and audits by state regulatory authorities have adversely impacted market sentiment and directly affected pharmaceutical enterprises, resulting in short-term revenue declines.
- **Delays in Product Registration:** Core and newly developed products are facing difficulties and delays in obtaining marketing authorizations, significantly affecting revenue growth, output expansion, and efforts to attract new customers.

2. 2025 Production and Business Plan with Key Performance Indicators:

No.	INDICATOR	UNIT	VALUE
I	Industrial Production	Unit of product	513,703,843
1	Plant No. 1	Unit of product	87,055,738
2	Plant No. 2	Unit of product	426,648,105
II	Total Sales Value	VND	299,907,000,113
III	Cost of Goods Sold	VND	223,094,819,228
IV	Total Gross Profit	VND	76,812,180,885
V	Total Selling Expenses	VND	5,009,034,126
	Financial Expenses	VND	3,850,000,000
VI	Administrative Expenses	VND	55,049,459,188
VII	Profit Before Tax	VND	12,903,687,571

3. Operational Orientation:

- Continue implementing the streamlining restructuring project and deploying the ERP enterprise resource planning system with the aim of modernizing the management model, optimizing operational efficiency, and standardizing production and business processes in the direction of comprehensive digitalization.
- Continue seeking customers, expanding cooperation with domestic and international partners; maintain production volume with major customers; develop export markets through international trade promotion activities.

- Develop new products, conduct research to improve formulations and production processes of existing products. 2025 plan includes tasks related to research and development:

No.	Description	Unit	Quantity
1	Dossiers granted new marketing authorization numbers	Dossier	23
2	Dossiers registered for renewal	Dossier	10
3	Registration of dietary supplements and cosmetics	Dossier	8
4	Dossiers for modifications and supplements	Dossier	80
5	Implementation of new product manufacturing	Product	20
6	Improvement of manufacturing formulas and production procedures	Product	3

- Continue reviewing professional regulations, procedures, and technical guidelines to ensure full compliance with GMP, GSP, GDP requirements and corporate governance standards. Standardize products to ensure consistent product quality, and minimize violations or recalls due to quality issues.
- Manage production efficiently to avoid waste, reduce material consumption, and optimize labor utilization to lower production costs and enhance product competitiveness.
- Develop inventory and procurement plans with optimal quantities to benefit from suppliers' preferential policies, reduce input costs, and lower the budget for purchasing raw materials and packaging.
- Effectively implement financial solutions related to cash flow management, inventory, and outstanding debts; restructure loans to ensure adequate capital for production, business operations, and investment activities in 2025.

The above is the report of the Board of Management on the business performance in 2024 and the orientation for the implementation of the 2025 business plan.

Respectfully proposes to the General Meeting of Shareholders for consideration and approval.

Recipients:

- BOD
- BOM
- Shareholders
- SSC
- Archived: Secretary


GENERAL DIRECTOR
MAI NHAT THANH



№: 03/2025/BC-MED

Hanoi, 30 June, 2025

**REPORT OF THE BOARD OF SUPERVISORS
ON ITS 2024 ACTIVITIES AND SUPERVISORY WORK, ALONG
WITH THE PROPOSED PLAN FOR 2025**

To: The General Meeting of Shareholders

- Pursuant to the Law on Enterprises and the Charter of Mediplantex National Pharmaceutical Joint Stock Company stipulating the functions and authority of the Board of Supervisors;

- Pursuant to the Resolution of the 2024 General Meeting of Shareholders and the Resolutions of the Board of Directors in 2024;

- Pursuant to the business performance results and the 2024 financial statements audited by AASC Auditing Firm Company Limited;

The Board of Supervisors (BOS) of Mediplantex National Pharmaceutical Joint Stock Company respectfully submits to the Annual General Meeting of Shareholders (GMS) the report on its activities in 2024 and the proposed plan for 2025, with the following key contents:

I. Organization and Activities of the Board of Supervisors:

1. Personnel of the Board of Supervisors:

The Board of Supervisors consists of 3 members, including:

- Mr. Ho Ngoc Tuan : Head of the Board of Supervisors
- Ms. Ha Thi Bich Hanh : Member of the Board of Supervisors
- Ms. Do Ngoc Thuy : Member of the Board of Supervisors

2. Activities of the Board of Supervisors:

During the year, the Board of Supervisors fully performed its duties and responsibilities as assigned by the General Meeting of Shareholders, specifically overseeing, inspecting, and supervising the Company's governance, management, and business operations. The Board operated with a strong sense of responsibility, clearly delegated tasks to each member, and appointed representatives to attend meetings of the Board of Directors (BOD) and the Board of Management (BOM).

The Board of Supervisors maintained full and regular working relations with the BOD and the General Director in business operations, monitoring the Company's activities to ensure compliance with applicable laws. It also regularly exchanged

information with the BOD and General Director regarding the implementation of business plans and resolutions approved by the General Meeting of Shareholders.

Based on its functions and duties as stipulated by the Law on Enterprises, the Company's Charter, and the Regulations on Organization and Operation of the Board of Supervisors, the Board carried out the following activities during the year:

- Attended the Company's Annual General Meeting of Shareholders.
- Participated in regular and extraordinary meetings of the Board of Directors.
- Monitored financial and accounting activities, including review of the semi-annual and annual financial statements of the Company.
- Supervised the activities of the BOD and the Board of Management in accordance with the law and resolutions of the General Meeting of Shareholders.
- Oversaw the Company's information disclosure in compliance with legal regulations.
- Proposed the selection of an independent auditing firm to audit the Company's annual and semi-annual financial statements; assessed the financial statements before and after the audit.
- Provided input on the development of operating regulations for the Company by the BOD and the Board of Management.
- Cooperated with relevant departments to inspect and assess business operations.
- Held regular and extraordinary meetings of the Board of Supervisors to review, discuss, and evaluate the Company's performance.
- Performed other duties in accordance with the functions and responsibilities of the Board of Supervisors.

II. Evaluation by Task Group:

1. Evaluation by the BOS on the Activities of the BOD:

- Governance activities were carried out in accordance with the law, the Company's Charter, and the resolutions of the General Meeting of Shareholders.

- The BOD ensured transparency and openness in management, with a strategic focus on business development and efficiency.

- The BOD held regular meetings with clear agendas, documented minutes, and issued resolutions instructing the General Director to implement decisions. However, in the past period, the BOD was unable to organize meetings as regularly

planned due to the health condition of the Chairman. The BOS recommends that the BOD resume regular meetings as prescribed.

- During the year, the BOD amended, supplemented, and issued several regulations, documents, resolutions, and decisions, providing a structured, focused, and unified foundation for corporate governance.

2. Evaluation by the BOS on the General Director's Implementation of Resolutions of the GMS and the BOD:

- The General Director implemented various measures to strengthen financial management by controlling expenses, monitoring customer receivables, and managing operational activities in line with the objectives set by the General Meeting of Shareholders and the BOD.

- Took the initiative in executing the business plan, fully fulfilled obligations to the State and shareholders, and paid attention to employee welfare.

- Organized the year-end review conference to comprehensively evaluate business operations, identify limitations and shortcomings, and propose appropriate solutions and corrective actions.

- Focused on addressing internal weaknesses of the Company to improve operational efficiency and reduce costs.

- Regarding investment and co-investment projects that are behind schedule, the Board of Supervisors submitted recommendations to the BOD and the Board of Management, requesting a thorough review to ensure legal compliance and investment efficiency.

- For several resolutions issued by the BOD that have not yet been implemented, the Board of Supervisors recommends that the BOM promptly report back to the BOD.

III. Review and Evaluation of Financial Statements:

1. Preparation and Audit of Financial Statements:

- The Company's financial statements were prepared in accordance with current Vietnamese Accounting Standards. The annual and semi-annual financial statements were audited by AASC Auditing Firm Company Limited.

- The Board of Supervisors reviewed the financial statements and concurred with the reported business results. According to the audit opinion provided by AASC, the Company's financial statements were presented fairly, accurately, completely, and clearly, and were in compliance with applicable accounting standards.

However, the auditing firm issued a qualified opinion on the Company's 2024 audited financial statements, not an unqualified opinion, due to a limitation in the audit

scope related to two business cooperation contracts: Contract No. 68/HDHTKD dated June 1, 2017 (cooperation in developing the project at the land lot located at 190 Dinh Thon Street, My Dinh 1 Ward, Nam Tu Liem District) and Contract No. 35/2009/HĐHT dated December 25, 2009 (cooperation in developing the project at the land lot located at 118 Nguyen Van Troi Street, Phuong Liet Ward, Thanh Xuan District). As the Company is currently working with its partners and relevant authorities on the implementation of these contracts, the information has not yet been provided to the auditors.

Regarding this matter, the Board of Supervisors has recommended that the Company engage a consulting firm to promptly resolve the issue and protect the Company's rights and interests in accordance with regulations. In addition, the Board of Supervisors has submitted its recommendations on this matter to the BOD and BOM, and requested that the BOD and BOM take appropriate action and implement necessary solutions.

2. Business Performance Results:

The Company closely followed the business targets set by the GMS and focused on implementing solutions to enhance production capacity, improve product quality, reduce costs, and increase operational efficiency.

- Specific business results for the period:

Unit: billion VND

Indicator	Actual 2023	Actual 2024	% Actual 2024 vs. 2023	Plan 2024	% Plan Completion
Revenue	402.741	443.135	110.03%	360.724	122.8%
Earning before tax	14.923	19.418	130.12%	16.117	120.5%
Net Income	11.743	15.246	129.83%	12.668	120.35%

General assessment of business performance during the period:

Revenue and profit increased compared to the previous year. Revenue and profit also exceeded the planned targets.

3. Key Financial Indicators as of December 31:

No.	Indicator	Unit	Year	
			2024	2023
I	Asset Structure			
1	Current Assets / Total Assets	%	50.24	57.52
2	Non-current Assets / Total Assets	%	49.76	42.48
II	Capital Structure			

1	Liabilities / Total Capital	%	34.32	45.36
2	Owner's Equity / Total Capital	%	65.68	54.64
III	Liquidity Ratios			
1	Current Ratio (Current Assets / Short-term Liabilities)	Times	1.46	1.27
2	Quick Ratio ((Cash + Short-term Financial Investments) / Short-term Liabilities)	Times	0.32	0.23
3	Cash Ratio ((Cash + Marketable Securities) / Short-term Liabilities)	Times	0.25	0.16
VI	Operating Ratios			
1	Pre-tax Profit / Revenue	%	4.38	3.71
2	After-tax Profit / Revenue	%	3.44	2.92

IV. Recommendations for the Board of Directors and the General Director to continue addressing in the coming period:

- The BOD should consider developing a long-term business strategy to enhance proactiveness in operations.
- Improve and strengthen training and recruitment of qualified and experienced staff, as well as highly skilled technical workers, to support future business and production activities.
- Continue implementing more effective measures to recover due receivables and bad debts.
- Accelerate the implementation of the Pharmaceutical Science and Technology Center and the EU-GMP-standard Pharmaceutical Manufacturing Plant Project to bring it into efficient operation as soon as possible.

V. Work Plan of the Board of Supervisors for 2025:

- Perform inspection and supervision duties over the governance and management activities of the Board of Directors and the Board of Management in accordance with the Company's Charter and the Law on Enterprises;
- Monitor the implementation of resolutions of the General Meeting of Shareholders and resolutions of the Board of Directors in the course of business operations, based on legal regulations and the Company's Charter;
- Review the appropriateness of internal documents and management regulations and their practical application to ensure alignment with the resolutions of the General Meeting of Shareholders. Propose amendments or supplements to internal regulations if deemed necessary;
- Examine accounting records, vouchers, and other Company documents when necessary or upon request of the General Meeting of Shareholders;

- Propose the selection of an independent auditing firm to audit the Company's semi-annual and annual financial statements;
- Review and evaluate financial statements and the Company's business performance on a quarterly, semi-annual, and annual basis;
- Maintain close coordination between the Board of Supervisors, the Board of Directors, the Board of Management, and other relevant units within the Company;
- Participate in major Company activities to stay informed about business operations;
- Attend BOD meetings and quarterly briefings to stay up to date on the Company's situation.

VI. General Assessment of the Activities of the Board of Supervisors:

- The Board of Supervisors performed its functions and duties in accordance with the Company's Charter and the relevant provisions of the Law on Enterprises relating to the Board of Supervisors.

- The Board of Supervisors fulfilled the responsibilities entrusted to it by shareholders, particularly in overseeing business operations and the effective use of capital.

- The performance of the Board of Supervisors during the term was the result of the efforts of each member, as well as the trust, support, and facilitation provided by the Board of Directors, the General Director, departments, and all employees of the Company.

On behalf of the Board of Supervisors, I would like to sincerely thank the General Meeting of Shareholders, the Board of Directors, and the General Director for their trust, support, and cooperation throughout the past year, which enabled the Board of Supervisors to fulfill its duties effectively.

Respectfully!

Recipient:

- Shareholders;
- BOD; BOM;
- BOS;
- Archived: BOS; Secretary; Office.

ON BEHALF OF THE BOARD OF SUPERVISORS

HEAD OF THE BOARD



Ho Ngoc Tuan

No.: 01/2025/TTr-DHDCD

SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

Hanoi, June 30, 2025

PROPOSAL

Re: Approval of the 2024 Audited Financial Statements

**To: The General Meeting of Shareholders
of Mediplantex National Pharmaceutical Joint Stock Company**

- Pursuant to the Law on Enterprises No. 59/2020/QH14 adopted by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020, and effective from January 1, 2021, as amended by Law No. 03/2022/QH15 adopted by the National Assembly on January 11, 2022;
- Pursuant to the Charter on organization and operation of Mediplantex National Pharmaceutical Joint Stock Company;
- Pursuant to the 2024 financial statements of Mediplantex National Pharmaceutical Joint Stock Company, audited by AASC Auditing Firm Company Limited.

The Board of Directors respectfully submits to the General Meeting of Shareholders of the Company for consideration and approval the following matter:

In accordance with the Resolution of the 2024 Annual General Meeting of Shareholders regarding the selection of an independent auditing firm for the 2024 financial statements, the Company appointed AASC Auditing Firm Company Limited to conduct the independent audit of the 2024 financial statements.

The Company's 2024 financial statements were independently audited by AASC Auditing Firm Company Limited, with the audit report signed on March 21, 2025.

Respectfully submits to the General Meeting of Shareholders for consideration and approval./.

Recipients:

- Company Shareholders;
- BOD; BOM;
- BOS;
- Archived: Company Secretary.



Thai Khắc Minh

No.: 02/2025/TTr-DHDCD

SOCIALIST REPUBLIC OF VIETNAM

Independence – Freedom – Happiness

Hanoi, June 30, 2025

PROPOSAL

Re: Selection of the Independent Auditor for the 2025 Financial Statements

To: The General Meeting of Shareholders

of Mediplantex National Pharmaceutical Joint Stock Company

- Pursuant to the Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020, as amended by Law No. 03/2022/QH15 passed by the National Assembly on January 11, 2022;
- Pursuant to the Charter on Organization and Operation of Mediplantex National Pharmaceutical Joint Stock Company.

The Board of Supervisors of Mediplantex National Pharmaceutical Joint Stock Company respectfully submits to the General Meeting of Shareholders for consideration and approval the following matter:

In order to ensure proactivity in selecting an appropriate auditing firm that meets the Company's requirements regarding the timing and quality of auditing services for the financial statements of the fiscal year 2025, the Board of Supervisors respectfully proposes that the General Meeting of Shareholders consider and approve the following contents:

1. Approval of criteria for selecting the independent auditing firm for the 2025 Financial statements:
 - The auditing firm must be an independent audit enterprise included in the list of entities eligible to provide audit services as announced by the Ministry of Finance at the time of selection. It must fully meet all professional standards and conditions, possess a team of qualified auditors, and be approved by the State Securities Commission to audit public interest entities operating in the securities sector in 2025.
 - The firm must have a strong reputation and extensive experience in the field.
 - The firm must not have any conflicts of interest in connection with auditing the Corporation's financial statements.
 - The proposed audit fee must be competitive and appropriate to the content, scope, and timeline of the audit engagement.
2. Approval of the following list of auditing firms proposed to conduct the audit of the financial statements for the fiscal year 2025 and the review of the quarterly and semi-annual financial statements (if required by State regulatory authorities) for Mediplantex National Pharmaceutical Joint Stock Company, including:
 - 1.1. KPMG Company Limited;



- 1.2. AASC Auditing Firm Company Limited;
- 1.3. PWC (Vietnam) Company Limited;
- 1.4. Viet Nam Auditing & Evaluation Company Limited;
- 1.5. An Viet Auditing Company Limited.

1.6. Other audit firms included in the list of audit companies approved by the State Securities Commission to audit public interest entities in the securities sector for the year 2025.


3. Estimated auditing fee: From VND 200,000,000 to VND 500,000,000.
4. The Board of Supervisors respectfully submits to the General Meeting of Shareholders a proposal to authorize the Board of Directors to select one of the aforementioned auditing firms to conduct the audit and review of the 2025 financial statements. In the event that the selected auditing firm is unable to continue the audit and review, or if the Board of Directors deems that the selected firm cannot ensure timely issuance of the reports, the Board of Supervisors seeks the General Meeting's authorization for the Board of Directors to change the auditing firm, provided that the replacement meets the required criteria and is selected from the list previously approved by the General Meeting of Shareholders. Any change of auditing firm will be disclosed as an extraordinary information disclosure in accordance with the prevailing laws and regulations on information disclosure in the securities market.
5. The Board of Directors authorizes the General Director / Legal Representative to sign the audit contract with the selected auditing firm.

Respectfully submits to the General Meeting of Shareholders for consideration and approval.

Recipients:

- *Company Shareholders;*
- *BOD; BOM;*
- *BOS;*
- *Archived: Company Secretary.*

ON BEHALF OF
THE BOARD OF SUPERVISORS
HEAD



Ho Ngoc Tuan





CÔNG TY CỔ PHẦN DƯỢC TRUNG ƯƠNG MEDIPLANTEX

Địa chỉ: 358 Đường Giải Phóng - Quận Thanh Xuân - Hà Nội

Website: <http://www.mediplantex.com>

No.: 03/2025/TTr-DHDCD

SOCIALIST REPUBLIC OF VIETNAM

Independence – Freedom – Happiness

Hanoi, June 30, 2025

PROPOSAL

Re: Approval of the profit distribution plan and dividend payout ratio for 2024, and the proposed profit distribution plan and dividend payout ratio for 2025

**To: The General Meeting of Shareholders
of Mediplantex National Pharmaceutical Joint Stock Company**

Pursuant to:

- *The Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam, on June 17, 2020, effective as of January 1, 2021, and amended by Law No. 03/2022/QH15 passed by the National Assembly on January 11, 2022;*
- *The Law on Securities No. 54/2019/QH14 was passed by the National Assembly of the Socialist Republic of Vietnam on November 26, 2019, and came into effect on January 1, 2021; as amended by Law No. 56/2024/QH15, which was adopted by the National Assembly of the Socialist Republic of Vietnam on November 29, 2024.*
- *The Charter on the organization and operation of Mediplantex National Pharmaceutical Joint Stock Company;*
- *The 2024 financial statements of Mediplantex National Pharmaceutical Joint Stock Company audited by AASC Auditing Firm Company Limited;*
- *The 2024 business and production results and the implementation plan for 2025.*

The Board of Directors respectfully submits to the General Meeting of Shareholders for consideration and approval the following matter:

I. PROFIT DISTRIBUTION PLAN FOR 2024:

Indicators	Percentage (%)	Year 2024 (Unit: VND)
1. Profit before tax in 2024		19,418,107,894

2. Corporate income tax payable in 2024		4,171,341,682
3. Profit after tax in 2024		15,246,766,212
4. Profit distribution in 2024		15,246,766,212
4.1. Bonus allocation to the Board of Management		246,584,856
<i>Bonus for Achievement of Profit Target</i>	1%	128,938,363
<i>Additional Bonus: 5% of the value of profit exceeding the planned target</i>		117,646,493
4.2. Bonus allocation to the Board of Directors and the Board of Supervisors		246,584,856
<i>Bonus for achievement of profit target</i>	1%	128,938,363
<i>Additional bonus: 5% of the value of profit exceeding the planned target</i>		117,646,493
4.3. Allocation to the Development Investment Fund	0%	
4.4. Remaining profit for dividend distribution		14,753,596,500
5. Retained earnings from previous years		503,923,388
6. Total profit for dividend distribution up to the end of 2024		15,257,519,888
7. Proposed dividend distribution	12% of charter capital	14,892,000,000
8. Retained earnings for 2025		365,519,888

II. DIVIDEND PAYOUT RATIO FOR 2024

The Board of Directors respectfully submits to the General Meeting of Shareholders for approval the proposal to distribute dividends in cash and to authorize the Board of Directors to determine and implement the timing of the dividend payment. The proposed dividend payment plan is as follows:

- **Dividend payout ratio: 12%**
- **Total dividend payment amount: 14,892,000,000 VND**

III. PROPOSAL FOR 2025

- Based on the 2025 business and production plan of Mediplantex National Pharmaceutical

Joint Stock Company, the Board of Directors proposes the allocation of bonuses and the dividend payout rate for 2025 as follows:

Projected for 2025	Percentage %	Amount VND
I. Profit Before Tax 2025		12,903,687,571
II. Profit After Tax 2025		10,322,950,057
1. Allocation for bonus to the Board of Management	1%	103,229,501
2. Allocation for bonus to the Board of Directors and the Board of Supervisors	1%	103,229,501
3. Allocation to the Development Investment Fund	0	0
4. Remaining profit for dividend distribution	8% of charter capital	9,928,000,000
5. Retained earnings for 2026		188,491,056

- The allocation of bonuses to the Board of Management and to the Board of Directors and the Board of Supervisors at the above-mentioned rates shall only be implemented if the profit after tax in 2025 reaches 90% to 100% of the 2025 approved plan.
- In the event that the 2025 performance exceeds the plan approved by the General Meeting of Shareholders:
 - + Additional bonus for the Board of Management at the rate of 05% of the excess amount over the plan.
 - + Additional bonus for the Board of Directors and the Board of Supervisors at the rate of 05% of the excess amount over the plan.

Respectfully submits to the General Meeting of Shareholders for consideration and approval./.

Recipients:

- Shareholders of Mediplantex National Pharmaceutical Joint Stock Company;
- BOD, BOS, BOM, Company Secretary
- Archived: Office, BOD.



**ON BEHALF OF
THE BOARD OF DIRECTORS**

Thai Khắc Minh

No.: 04/2025/TTr-DHDCD

SOCIALIST REPUBLIC OF VIETNAM

Independence – Freedom – Happiness

Hanoi, June 30, 2025

PROPOSAL

Re: Approval of remuneration for the Board of Directors and the Board of Supervisors for 2025

**To: The General Meeting of Shareholders
of Mediplantex National Pharmaceutical Joint Stock Company**

Pursuant to:

- Pursuant to the Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam, on June 17, 2020, effective as of January 1, 2021, and amended by Law No. 03/2022/QH15 passed by the National Assembly on January 11, 2022;
- Pursuant to the Charter on the organization and operation of Mediplantex National Pharmaceutical Joint Stock Company;
- Pursuant to the 2024 financial statements of Mediplantex National Pharmaceutical Joint Stock Company audited by AASC Auditing Firm Company Limited;
- The 2024 business and production results and the implementation plan for 2025.

The Board of Directors respectfully submits to the General Meeting of Shareholders the following matter for consideration and approval:

In regard to the activities of the Board of Directors and the Board of Supervisors in carrying out their assigned duties in 2024, the Company hereby reports the remuneration levels of each member of the Board of Directors and the Board of Supervisors for the year 2024:

❖ **Remuneration of Each Member of the Board of Directors and the Board of Supervisors in 2024:** *has been detailed in the audited financial statements for 2024.*

No.	Items	Amount (VND)
1	Unpaid remuneration of the Board of Directors of the previous year carried forward	0

2	Remuneration of the Board of Directors in 2024	646,000,000
2.1	Board of Directors' remuneration deducted in 2024	418,000,000
2.2	Remaining Board of Directors' remuneration carried forward to 2025	228,000,000
3	Remuneration of the Board of Supervisors, in 2024	204,000,000
3.1	Board of Supervisors and Secretary's remuneration deducted in 2024	152,000,000
3.2	Remaining Board of Supervisors and Secretary's remuneration carried forward to 2025	52,000,000

Other entitlements of the members of the Board of Directors and the Board of Management shall be implemented in accordance with the provisions of law, the Company's Charter, and internal regulations.

❖ **Proposed Remuneration for 2025:**

To ensure the effective operation of the Board of Directors and the Board of Supervisors in carrying out their assigned duties in 2025, and based on the business plan of Mediplantex National Pharmaceutical Joint Stock Company for 2025, as well as relevant regulations of the State, the Company's Charter, and internal regulations, the Board of Directors respectfully submits for approval the proposed total remuneration for 2025:

Remuneration	Amount
Member of the Board of Directors	646,000,000
Member of the Board of Supervisors and Secretary	204,000,000
Total	850,000,000



Respectfully submits to the General Meeting of Shareholders for consideration and approval./.

Recipients:

- Shareholders of Mediplantex National Pharmaceutical Joint Stock Company;
- BOD, BOS, Company Secretary
- Archived: Office, BOD.



Thai Khắc Minh

No.:05/2025/TTr-DHDCD

SOCIALIST REPUBLIC OF VIETNAM

Independence – Freedom – Happiness

Hanoi, June 30, 2025

PROPOSAL

Re: Approval of the Dismissal and Election for the Additional Members of the Board of Directors for the 2024 – 2029 Term

**To: The General Meeting of Shareholders
of Mediplantex National Pharmaceutical Joint Stock Company**

- Pursuant to the Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam, on June 17, 2020, as amended by Law No. 03/2022/QH15 passed by the National Assembly on January 11, 2022;

- Pursuant to the Charter on Organization and Operation of Mediplantex National Pharmaceutical Joint Stock Company;

- Pursuant to the Regulation on the Operation of the Board of Directors of the Company;

- Based on the letter of resignation submitted by the member of the Board of Directors to the Board of Directors;

The Board of Directors respectfully proposes to the General Meeting of Shareholders of the Company for consideration and approval of the following matters:

1. Based on the resignation letter submitted by a member of the Board of Directors, the Board respectfully proposes that the General Meeting of Shareholders approve the dismissal of:

Mr. Tran Xuan Dinh - Member of the Board of Directors for the 2024–2029 term

Reason for dismissal Voluntary resignation

Upon the approval of Mr. Tran Xuan Dinh's resignation, the Board of Directors of Mediplantex National Pharmaceutical Joint Stock Company for the 2024–2029 term will consist of only 03 members, thereby failing to meet the structural requirements of the Board of Directors as prescribed by the Company's Charter. Accordingly, the Board of Directors deems it necessary to propose the election of an additional member to the Board of Directors for the 2024–2029 term.

2. The Board of Directors respectfully proposes to the General Meeting of Shareholders of the Company for consideration and approval the election of additional members to the Board of Directors for the 2024–2029 term, as follows:

- Number of additional members to be elected to the BOD: 02 member



- Criteria for selecting a member of the BOD: In accordance with Clause 2, Article 155 of the Law on Enterprises and Article 7 of the Regulations on the Operation of the BOD.
- Number of candidates: Unlimited.

Based on the nomination and self-nomination results submitted by shareholders and groups of shareholders in accordance with the Company's Charter, and considering the competence, qualifications, and reputation of the nominees, and in compliance with the criteria for BOD members as prescribed by the Company's Regulations on the Operation of the BOD and applicable laws, the BOD respectfully proposes to the General Meeting of Shareholders for approval the List of Candidates for the election of two (02) additional member of the BOD for the remainder of the 2024 – 2029 term as follows:

- Ms: Nguyen Ngoc Xuan Trang Candidate for the Board of Directors
- Ms: Tran Nguyen Hoàng Phuc Candidate for the Board of Directors

Curricula Vitae of the Candidates Attached to This Proposal.

Respectfully proposes to the General Meeting of Shareholders for consideration and approval./.

Recipients:

- Company Shareholders;
- BOD; BOS;
- Archived: Company Secretary.

**ON BEHALF OF
THE BOARD OF DIRECTORS**



Thai Khắc Minh



THE SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom - Happiness

CURRICULUM VITAE

(For candidates nominated/elected to the Board of Directors Directors)

1. Full name: ~~Nguyen~~ Ngoc Xuan Trang

Gender: Female

2. Date of birth: 18/05/1966

Noi sinh: Long An.

3. Nationality: Vietnam

4. ID Card/Citizen ID/Passport: 079166010931

Date of issue: 29/04/2021

Place of issue: Police Department on Administrative Management of Social Order

5. Permanent residence: 506/15/34, 3 Thang 2 Street, District 10, Ho Chi Minh City

6. Telephone number: Email:

7. Academic qualifications: 12/12

8. Professional qualifications:

9. Work experience:

Period	Employment History, Profession, and Positions Held (what, where)	Note
January 2010 – present	Director of An Hy Pharmaceutical Company Limited	

10. Current Position at Mediplantex National Pharmaceutical Joint Stock Company (if any): None

11. Current Positions Held at Other Organizations:

Company Name	Address	Business Registration Certificate	Date/Place of Issuance	Position	Ownership Ratio / Capital Contribution
An Hy Pharmaceutical Company Limited	506/15/34, 3/2 Street, Ward 14, District 10, HCM	0309738339	22/05/2017, Department of Planning and Investment of HCMC	Director	

12 Number of shares held (as of the record date) at Mediplantex National Pharmaceutical Joint Stock Company: 3,543,044 shares, accounting for 28.5% of the charter capital, including:

+ Shares held as representative (on behalf of state/strategic shareholder/other organization): shares

+ The number of shares personally owned: 3,543,044 shares

13 Other commitments to hold (if any):

14 List of related persons to the applicant ^{*}:

No.	Name of individual/organization	ID Number of the Shareholder / Citizen ID	Date of Issue	Place of Issue	Number of Shares Held, Ownership Percentage of the	Relationship to the Declarant
-----	------------------------------------	--	------------------	-------------------	---	-------------------------------------

					Company's Charter Capital	
1	Tran Hoang Thuong	340656440	28/06/2002	Dong Thap province's public security		Father-in-law
2	Luong Thi Ngoc Xoan	340203158	13/04/1999	Dong Thap province's public security		Mother-in-law
3	Tran Hoang Dung	087060006964	10/07/2021	Police Department for Administrative Management of Social Order	1,000,000	Husband
4	Tran Nguyen Hoang Phuc	079191020545	24/04/2021	Police Department for Administrative Management of Social Order	2,761,900	Daughter
5	Tran Xuan Dinh	079091010916	23/09/2022	Police Department for Administrative Management of Social Order	0	Son-in-law
6	Tran Nguyen Hoang An	079094025506	22/11/2021	Police Department for Administrative Management of Social Order	20,000	Son
7	Tran Nguyen Hoang Hy	079305028978	15/03/2021	Police Department for Administrative Management of Social Order	47,000	Daughter
8	Tran Nguyen Hoang An	012819160	03/07/2014	Ho Chi Minh city's public security	87,500	Daughter
9	Nguyen Ngoc Minh Trang				0	Younger Sister
10	Nguyen Hong Hien Nhan				0	Younger Brother
11	Nguyen Ngoc Thao Trang				0	Younger Sister

010
ÔNG
PH
RUNG
PLAN
Mj
HỒ H

12	An Hy Pharmaceutical Company Limited	0309738339	22/05/2017	Department of Planning and Investment of Ho Chi Minh City	0	Director
----	--------------------------------------	------------	------------	---	---	----------

15. Related interests with Mediplantex National Pharmaceutical Joint Stock Company (if any):
None

16. Conflicting interests with Mediplantex National Pharmaceutical Joint Stock Company (if any): None

I hereby affirm that the above statements are completely true and accurate. If any information is found to be false, I fully accept responsibility before the law.

**CONFIRMATION OF THE LOCAL
AUTHORITIES OR WORKPLACE
(IF ANY)**

DECLARANT
(Signature and full name)









SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

CURRICULUM VITAE

(For candidates nominated/elected to the Board of Directors)

1. Full name: Tran Nguyen Hoang Phuc Gender: Female
2 Date of birth: 02/12/1991 Place of birth: Ho Chi Minh City
3. Nationality: Vietnamese
4. ID/Passport number: 079191020545 Date of issue: April 24, 2021
Place of issue: Police Department for Administrative Management of Social Order
5. Permanent residence: 506/15/34, February 3 Street, District 10, Ho Chi Minh City
6. Telephone number: Email:
7. Academic qualifications: 12/12
8. Professional qualifications: Bachelor's degree in Biochemistry
9. Work experience

Period	Work experience, profession, and positions held (what was done, where it was done)	Note
01/07/2024- 29/07/2024	Assistant to the General Director, Mediplantex National Pharmaceutical Joint Stock Company	
01/08/2024 - present	Head of Legal and Inspection Department, Mediplantex National Pharmaceutical Joint Stock Company	
01/11/2024 - present	Head of Organization and Administration Department, Mediplantex National Pharmaceutical Joint Stock Company	

10. Current position at Mediplantex National Pharmaceutical Joint Stock Company (if any):

Head of Organization and Administration Department cum Head of Legal Department

11. Current position at other entities or organizations: None

Company name	Address	Business Registration Certificate	Date/Place of Issue	Position	Ownership Ratio / Capital Contribution

12. The number of shares held and represented (as of the record date) at Mediplantex National Pharmaceutical Joint Stock Company: 2,761,900 shares, accounting for 22.26% of the charter capital. Of which:

+ Shares held as representative (on behalf of state/strategic shareholder/other organization): shares

+ The number of shares personally owned: 2,761,900 shares

13. Other commitments to hold (if any):

14. List of related persons to the applicant * :

No.	Name of individual/organization	ID card number/Citizen ID/Passport(for individuals) or Business Registration Certificate number/Operating License or equivalent legal document (for organizations)	Date of issue	Place of issue	Number of shares held, ownership percentage of the company's charter capital (if any)	Relationship
1	Tran Hoang Dung	087060006964	10/07/2021	Police Department for Administrative Management of Social Order	1,000,000	Father
2	Nguyen Ngoc Xuan Trang	079166010931	29/04/2021	Police Department for Administrative Management of Social Order	3,543,044	Mother
3	Vo Thi Thuy Phuong Loan	064168000050	11/08/2021	Police Department for Administrative Management of Social Order		Mother-in-law
4	Tran Xuan Dinh	079091010916	23/09/2022	Police Department for Administrative Management of Social Order		Husband
5	Tran Nguyen Hoang An	079094025506	22/11/2021	Police Department for Administrative Management of Social Order	20,000	Younger brother
6	Tran Nguyen Hoang Hy	079305028978	15/03/2021	Police Department for Administrative Management of Social Order	47,000	Younger sister

7	Tran Nguyen Hoang An	012819160	03/07/2014	Ho Chi Minh city's public security	87,500	Older sister
---	-------------------------	-----------	------------	---------------------------------------	--------	--------------

15. Related interests with Mediplantex National Pharmaceutical Joint Stock Company (if any):
None

16. Interests in conflict with Mediplantex National Pharmaceutical Joint Stock Company (if any): None

I hereby affirm that the above statements are completely true and accurate. If any information is found to be false, I fully accept responsibility before the law.

**CONFIRMATION OF THE LOCAL
AUTHORITIES OR WORKPLACE
(IF ANY)**

DECLARANT
(Signature and full name)



Tran Nguyen Hoang Phuc



MINUTES OF MEETING

2025 ANNUAL GENERAL MEETING OF SHAREHOLDERS

MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY

Company Name: Mediplantex National Pharmaceutical Joint Stock Company

Head Office: No. 358 Giai Phong Street, Phuong Liet Ward, Thanh Xuan District, Hanoi City

Enterprise Registration Certificate No.: 0100108430, initially issued by the Hanoi Department of Planning and Investment on April 12, 2005; 18th amendment registered on May 5, 2022

Time: 8:30 AM, June 30, 2025

Venue: Guest House of the Hanoi Capital Command, No. 99 Le Duan Street, Cua Nam Ward, Hoan Kiem District, Hanoi.

I. PARTICIPANTS, LEGALITY, AND VALIDITY OF THE GENERAL MEETING OF SHAREHOLDER

1. Participants:

Board of Directors (BOD): All members of the BOD were present at the General Meeting of Shareholders, including:

- Mr. Tran Nguyen Hoang An – Member of the BOD
- Ms. Nguyen Thi Thuy – Member of the BOD
- Mr. Thai Khac Minh – Independent Member of the BOD;

Board of Supervisors (BOS): All members of the BOS were present at the General Meeting of Shareholders, including:

- Mr. Ho Ngoc Tuan – Head of the BOS
- Ms. Ha Thi Bich Hanh – Member of the BOS
- Ms. Do Ngoc Thuy – Member of the BOS;

Board of Management: Members of the Board of Management present at the General Meeting of Shareholders included:

- Mr. Mai Nhat Thanh – General Director

- Mr. Le Thanh Lam

- Deputy General Director

Shareholders entitled to attend the 2025 Annual General Meeting of Shareholders according to the list finalized as of the record date, May 29, 2025, and duly authorized representatives of shareholders.

2. Legality and Validity of the General Meeting:

As of the opening time of the General Meeting at **08:40 a.m. on June 30, 2025**, there were **69** shareholders (including duly authorized representatives), representing **9,567,646** shares, corresponding to **9,567,646** votes (each ordinary share carries one vote), accounting for **77.0963%** of the total votes of all shareholders of Mediplantex National Pharmaceutical Joint Stock Company. Therefore, the 2025 Annual General Meeting of Shareholders is deemed legal, valid, and eligible to proceed in accordance with the content specified in Section A, Part II of these Minutes.

II. PROCEEDINGS OF THE GENERAL MEETING

A. Opening Procedures of the General Meeting of Shareholders:

1. **Ms. Nguyen Thi Thanh Van**, on behalf of the Organizing Committee of the General Meeting, announced the purpose of the meeting and introduced the delegates.
2. **Ms. Bui Thi Tuyet Lan**, on behalf of the Shareholder Eligibility Verification Committee, announced the shareholder attendance rate with the following result:
 - According to the attendance list as of **08:40 a.m, June 30, 2025**, there were **69** shareholders (including duly authorized representatives), representing **9,567,646** shares, corresponding to **9,567,646** voting rights (each ordinary share carries one voting right), accounting for **77.0963%** of the total voting rights of all shareholders of Mediplantex National Pharmaceutical Joint Stock Company.
 - Pursuant to the Law on Enterprises and the Company's Charter, with more than 50% of the voting shares represented at the meeting, the General Meeting of Shareholders is deemed legally and validly convened and eligible to proceed.
3. **Ms. Nguyen Thi Thanh Van** introduced **Mr. Thai Khac Minh** as the Chairman of the Meeting.
4. **Mr. Thai Khac Minh**, Chairman of the Meeting, introduced the members of the Presidium and the Secretariat:

Presidium:

- | | |
|-----------------------------------|------------|
| • Mr. Thai Khac Minh | - Chairman |
| • Mr. Tran Nguyen Hoang An | - Member |
| • Mr. Mai Nhat Thanh | - Member |

Secretariat:

- Ms. **Chu Huyen Trang** – Head
- Mr. **Nguyen Dinh Thanh** – Member

The General Meeting unanimously approved this composition with 100% of the total votes of shareholders attending and voting.

5. **Mr. Thai Khac Minh**, Chairman of the Meeting, presented the list of the Vote Counting Committee for approval by the General Meeting.

- The Presidium nominated the Vote Counting Committee to include three (03) members:

- Ms. **Ha Thi Bich Hanh** – Head
- Ms. **Duong Thi Minh Nguyet** – Member
- Ms. **Nguyen Thi Xiem** – Member

The General Meeting unanimously approved the Vote Counting Committee with 100% of the total votes of shareholders attending and voting.

6. **Mr. Thai Khac Minh**, on behalf of the Presidium, presented to the General Meeting:

- The working agenda of the General Meeting is as follows:
 - Introduction of the Secretariat of the General Meeting
 - Election of the Vote Counting Committee
 - Approval of the Agenda, the regulations on working and voting at the General Meeting;
 - Presentation of matters to be submitted for approval by the General Meeting of Shareholders:
 - Report of the Board of Directors on the Operational Results for 2024 and the Orientation and Tasks of the Board of Directors for 2025;
 - Report of the Board of Management on the 2024 business and production results and the implementation plan for 2025;
 - Report of the Board of Supervisors on its 2024 activities and supervisory work, along with the proposed plan for 2025;
 - Approval of the audited financial statements for 2024;
 - The selection of an independent auditing firm for the 2025 financial statements;
 - Approval of the profit distribution plan and dividend payout ratio for 2024, and the proposed profit distribution plan and dividend payout ratio for 2025;
 - Approval of remuneration for the Board of Directors and the Board of Supervisors for 2025;
 - Approval of the Dismissal and Election for the Additional Members of the Board of Directors for the 2024 – 2029 Term;
 - Break.
 - Announcement of the voting and election results at the General Meeting of Shareholders.

- Approval of the Minutes and Resolutions of the Meeting.
- Agenda of the General Meeting:
The General Meeting unanimously approved the agenda with 100% of the total votes of shareholders attending and voting.
- Regulations on working and voting at the 2025 Annual General Meeting of Shareholders:
The General Meeting unanimously approved the regulations on working and voting with 100% of the total votes of shareholders attending and voting.

B. Reports of the Board of Directors, Board of Management, and Matters Presented at the General Meeting of Shareholders:

1. **Mr. Thai Khac Minh – Member of the Board of Directors**, presented Report of the Board of Directors on the Operational Results for 2024 and the Orientation and Tasks of the Board of Directors for 2025;
2. **Mr. Mai Nhat Thanh – General Director** presented:
 - Report of the Board of Management on the 2024 business and production results and the implementation plan for 2025;
3. **Mr. Ho Ngoc Tuan – Head of the Board of Supervisors** – presented:
 - Report of the Board of Supervisors on its 2024 activities and supervisory work, along with the proposed plan for 2025;
 - Proposal for the approval of the audited financial statements for 2024;
 - Proposal for the selection of an independent auditing firm for the 2025 financial statements;
4. **Mr. Tran Nguyen Hoang An – Member of the Board of Directors** – presented the following proposals:
 - Proposal for the approval of the profit distribution plan and dividend payout ratio for 2024, and the proposed profit distribution plan and dividend payout ratio for 2025;
 - Proposal for the approval of remuneration for the Board of Directors and the Board of Supervisors for 2025;
5. **Mr. Thai Khac Minh – Member of the Board of Directors** – presented:
 - Approval of the Dismissal and Election for the Additional Members of the Board of Directors for the 2024 – 2029 Term;

C. Discussion of the reports and proposals presented at the General Meeting

1. **Mr. Thai Khac Minh – Chairman of the General Meeting** – chaired the discussion of the reports and proposals presented.

2. During the discussion session, attending delegates raised questions and received responses as follows:

Shareholders of Vietnam Pharmaceutical Corporation – JSC acknowledged the objective challenges currently faced by Mediplantex, particularly the psychological impact on the market, including distributors and partners, stemming from recent inspections within the pharmaceutical industry, as well as the temporary suspension of certain production activities. However, the Board of Management of Mediplantex is encouraged to maintain an optimistic outlook regarding market conditions in the near future and to make appropriate adjustments to the 2025 business plan. The proposed downward revisions—specifically a 32% decrease in net revenue and a 34% decrease in pre-tax profit compared to 2024—should be reconsidered to avoid excessive reductions. Furthermore, Mediplantex is advised to develop concrete measures aimed at improving production processes and enhancing product quality, thereby supporting revenue growth and strengthening operational efficiency in the remaining quarters of the year.

Response from the Presidium:

We sincerely thank Ms. Thuy – representative of Vietnam Pharmaceutical Corporation – JSC – for her constructive remarks. Since the beginning of the second quarter of 2025, the pharmaceutical sector in general, and the Company in particular, have faced numerous challenges. The large-scale inspections and audits conducted by regulatory authorities have significantly affected market sentiment and the confidence of distribution partners, leading to a projected decline in revenue from the end of Q2 into Q3, alongside a sharp increase in operating costs.

In response, the Board of Management will implement timely measures, including reinforcing relationships with existing customers, seeking new partners, improving and upgrading product quality, and increasing the number of new product registrations. The dividend payout for 2024 is 12% of charter capital, and the proposed payout for 2025 is 8% of charter capital. These figures are encouraging, especially in the current economically challenging climate. The Board of Directors and the Board of Management remain committed to striving for even greater achievements.

D. Voting, Vote Counting, and Announcement of Results

The General Meeting proceeded with voting and election by casting ballots into the ballot box, followed by a break while the Vote Counting Committee conducted the vote counting and announced the results.

The Vote Counting Committee announced the vote counting results as follows:

1. Voting Results:

At the time of voting, there were 93 shareholders (including duly authorized representatives), representing 9,667,291 shares, corresponding to 9,667,291 voting rights (each ordinary share carries one voting right), accounting for 77.8992% of the total voting rights of all shareholders of Mediplantex National Pharmaceutical Joint Stock Company.

Total ballots issued: 93, representing **9,667,291** voting ballots, accounting for **100%** of the total voting ballots present at the meeting.

Total ballots collected: 86, representing **9,639,588** voting ballots, accounting for **99.7134%** of the total voting ballots present at the meeting.

Total ballots not collected: 7, representing **27,703** voting ballots, accounting for **0.2866%** of the total voting ballots present at the meeting.

The detailed vote counting results for each item are as follows:

Item 01: Report of the Board of Directors on the Operational Results for 2024 and the Orientation and Tasks of the Board of Directors for 2025.

Voting Section

- Valid: **83**, representing: **9,629,088** votes, accounting for: **99.8911%** of the total number of votes of shareholders attending and voting the meeting.
 - + Agree: **80**, representing: **8,147,833** votes, accounting for: **84.5247%** of the total number of votes of shareholders attending and voting the meeting.
 - + Disagree: **0**, representing: **0** votes, accounting for: **0%** of the total number of votes of shareholders attending and voting the meeting.
 - + Abstain: **3**, representing: **1,481,255** votes, accounting for: **15.3664%** of the total number of votes of shareholders attending and voting the meeting.
- Invalid: **3**, representing: **10,500** votes, accounting for: **0.1089%** of the total number of votes of shareholders attending and voting the meeting.

Accordingly, **Item 01** was approved with a voting rate of **84.5247 %**.

Item 02: Report of the Board of Management on the 2024 business and production results and the implementation plan for 2025.

Voting Section:

- Valid: **84**, representing: **9,629,338** votes, accounting for: **99.8937%** of the total number of votes of shareholders attending and voting the meeting.
 - + Agree: **81**, representing: **8,148,083** votes, accounting for: **84.5273%** of the total number of votes of shareholders attending and voting the meeting.
 - + Disagree: **0**, representing: **0** votes, accounting for: **0%** of the total number of votes of shareholders attending and voting the meeting.
 - + Abstain: **3**, representing: **1,481,255** votes, accounting for: **15.3664%** of the total number of votes of shareholders attending and voting the meeting.

- Invalid: **2**, representing: **10,250** votes, accounting for: **0.1063%** of the total number of votes of shareholders attending and voting the meeting.

Accordingly, **Item 02** was approved with a voting rate of **84.5273%**.

Item 03: Report of the Board of Supervisors on its 2024 activities and supervisory work, along with the proposed plan for 2025.

Voting Section:

- Valid: **84**, representing: **9,629,338** votes, accounting for: **99.8937%** of the total number of votes of shareholders attending and voting the meeting.
 - + Agree: **82**, representing: **9,575,583** votes, accounting for: **99.3360%** of the total number of votes of shareholders attending and voting the meeting.
 - + Disagree: **0**, representing: **0** votes, accounting for: **0%** of the total number of votes of shareholders attending and voting the meeting.
 - + Abstain: **2**, representing: **53,755** votes, accounting for: **0.5576%** of the total number of votes of shareholders attending and voting the meeting.
- Invalid: **2**, representing: **10,250** votes, accounting for: **0.1063%** of the total number of votes of shareholders attending and voting the meeting.

Accordingly, **Item 03** was approved with a voting rate of **99.3360%**.

Item 04: Approval of the audited financial statements for 2024.

Voting Section:

- Valid: **84**, representing: **9,629,338** votes, accounting for: **99.8937%** of the total number of votes of shareholders attending and voting the meeting.
 - + Agree: **82**, representing: **9,575,583** votes, accounting for: **99.3360%** of the total number of votes of shareholders attending and voting the meeting.
 - + Disagree: **0**, representing: **0** votes, accounting for: **0%** of the total number of votes of shareholders attending and voting the meeting.
 - + Abstain: **2**, representing: **53,755** votes, accounting for: **0.5576%** of the total number of votes of shareholders attending and voting the meeting.
- Invalid: **2**, representing: **10,250** votes, accounting for: **0.1063%** of the total number of votes of shareholders attending and voting the meeting.

Accordingly, **Item 04** was approved with a voting rate of **99.3360%**.

Item 05: Approval of the selection of an independent auditing firm for the 2025 financial statements.

Voting Section:

- Valid: **84**, representing: **9,629,338** votes, accounting for: **99.8937%** of the total number of votes of shareholders attending and voting the meeting.
- + Agree: **82**, representing: **9,575,583** votes, accounting for: **99.3360%** of the total number of votes of shareholders attending and voting the meeting.
- + Disagree: **0**, representing: **0** votes, accounting for: **0%** of the total number of votes of shareholders attending and voting the meeting.
- + Abstain: **2**, representing: **53,755** votes, accounting for: **0.5576%** of the total number of votes of shareholders attending and voting the meeting.
- Invalid: **2**, representing: **10,250** votes, accounting for: **0.1063%** of the total number of votes of shareholders attending and voting the meeting.

Accordingly, **Item 05** was approved with a voting rate of **99.3360%**.

Item 06: Approval of the profit distribution plan and dividend payout ratio for 2024, and the proposed profit distribution plan and dividend payout ratio for 2025.

Voting Section:

- Valid: **84**, representing: **9,629,338** votes, accounting for: **99.8937%** of the total number of votes of shareholders attending and voting the meeting.
- + Agree: **82**, representing: **9,575,583** votes, accounting for: **99.3360%** of the total number of votes of shareholders attending and voting the meeting.
- + Disagree: **0**, representing: **0** votes, accounting for: **0%** of the total number of votes of shareholders attending and voting the meeting.
- + Abstain: **2**, representing: **53,755** votes, accounting for: **0.5576%** of the total number of votes of shareholders attending and voting the meeting.
- Invalid: **2**, representing: **10,250** votes, accounting for: **0.1063%** of the total number of votes of shareholders attending and voting the meeting.

Accordingly, **Item 06** was approved with a voting rate of **99.3360%**.

Item 07: Approval of remuneration for the Board of Directors and the Board of Supervisors for 2025.

Voting Section:

- Valid: **84**, representing: **9,629,338** votes, accounting for: **99.8937%** of the total number of votes of shareholders attending and voting the meeting.
- + Agree: **81**, representing: **9,572,833** votes, accounting for: **99.3075%** of the total number of votes of shareholders attending and voting the meeting.

- + Disagree: **0**, representing: **0** votes, accounting for: **0%** of the total number of votes of shareholders attending and voting the meeting.
- + Abstain: **3**, representing: **56,505** votes, accounting for: **0.5862%** of the total number of votes of shareholders attending and voting the meeting.
- Invalid: **2**, representing: **10,250** votes, accounting for: **0.1063%** of the total number of votes of shareholders attending and voting the meeting.

Accordingly, **Item 07** was approved with a voting rate of **99.3075%**.

Item 08: Approval of the Dismissal and Election for the Additional Members of the Board of Directors for the 2024 – 2029 Term.

Voting Section:

- Valid: **84**, representing: **9,629,338** votes, accounting for: **99.8937%** of the total number of votes of shareholders attending and voting the meeting.
 - + Agree: **82**, representing: **9,575,583** votes, accounting for: **99.3360%** of the total number of votes of shareholders attending and voting the meeting.
 - + Disagree: **0**, representing: **0** votes, accounting for: **0%** of the total number of votes of shareholders attending and voting the meeting.
 - + Abstain: **2**, representing: **53,755** votes, accounting for: **0.5576%** of the total number of votes of shareholders attending and voting the meeting.
- Invalid: **2**, representing: **10,250** votes, accounting for: **0.1063%** of the total number of votes of shareholders attending and voting the meeting.

Accordingly, **Item 08** was approved with a voting rate of **99.3360%**.

2. ELECTION RESULTS

At the time of electing an additional member to the Board of Directors for the 2024–2029 term, there were **93** shareholders (including duly authorized representatives), representing **9,667,291** shares, corresponding to **9,667,291** voting rights (one ordinary share carries one voting right), accounting for **77.8992%** of the total voting rights of all shareholders of Mediplantex National Pharmaceutical Joint Stock Company.

Total ballots issued: **93**, representing **9,667,291** voting ballots, accounting for **100.0000%** of the total voting ballots present at the meeting.

Total ballots collected: **87**, representing **9,639,598** voting ballots, accounting for **99.7135%** of the total voting ballots present at the meeting.

Total ballots not collected: 6, representing 27,693 voting ballots, accounting for 0.2865% of the total voting ballots present at the meeting.

Total number of valid ballots: 82, representing: 9,626,824 votes, accounting for: 99.8675% of the total number of votes of shareholders attending and voting the meeting:

Total number of invalid ballots: 5, representing: 12,774 votes, accounting for: 0.1325% of the total number of votes of shareholders attending and voting the meeting.

Election Vote Counting Results:

No.	FULL NAME	NUMBER OF VOTING RIGHTS	THE PERCENTAGE ON THE VOTES OF SHAREHOLDERS ATTENDING AND VOTING
1	Nguyen Ngoc Xuan Trang	12,035,360	124.8533%
2	Tran Nguyen Hoang Phuc	7,217,788	74.8764%

Accordingly, the list of elected candidates to the Board of Directors is as follows:

STT	FULL NAME	POSITION
1	Nguyen Ngoc Xuan Trang	BOD Member
2	Tran Nguyen Hoang Phuc	BOD Member

III. APPROVAL OF THE MINUTES AND RESOLUTIONS OF THE GENERAL MEETING OF SHAREHOLDERS

Presenter: **Ms. Chu Huyen Trang – Head of the Secretariat** – presented the Minutes and the Resolutions of the General Meeting of Shareholders to the assembly.

The General Meeting voted and unanimously approved the Minutes and Resolutions with 100% of the total voting rights of shareholders attending and voting.

The Meeting was concluded at 11:00 a.m. on the same day.

ON BEHALF OF THE SECRETARIAT



CHU HUYEN TRANG



CHAIRPERSON

THAI KHAC MINH

No.: 01/2025/NQ-DHDCD/MED

Hanoi, June 30, 2025

RESOLUTION
2025 ANNUAL GENERAL MEETING OF SHAREHOLDERS
MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY

Pursuant to:

- Pursuant to the Law on Enterprises No. 59/2020/QH14 adopted by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020, and effective from January 1, 2021, as amended by Law No. 03/2022/QH15 adopted by the National Assembly on January 11, 2022;
- Pursuant to the Law on Securities No. 54/2019/QH14 dated November 26, 2019, passed by the National Assembly of the Socialist Republic of Vietnam, as amended by Law No. 56/2024/QH15 passed by the National Assembly of the Socialist Republic of Vietnam on November 29, 2024, and its guiding documents;
- Pursuant to the Charter on organization and operation of Mediplantex National Pharmaceutical Joint Stock Company;
- Pursuant to the Minutes of the 2025 Annual General Meeting of Shareholders No. ... dated June 30, 2025;
- Pursuant to the Vote Counting Minutes of the 2024 Annual General Meeting of Shareholders of Mediplantex National Pharmaceutical Joint Stock Company dated June 30, 2025.

The 2025 Annual General Meeting of Shareholders (“AGM”) of Mediplantex National Pharmaceutical Joint Stock Company, convened at Guest House of the Hanoi Capital Command, No. 99 Le Duan Street, Cua Nam Ward, Hoan Kiem District, Hanoi, on June 30, 2025, hereby adopts the following Resolution:

RESOLUTION

Article 1. Approval of the following reports:

- Report of the Board of Directors on the Operational Results for 2024 and the Orientation and Tasks of the Board of Directors for 2025;
- Report of the Board of Management on the 2024 business and production results and the implementation plan for 2025;
- Report of the Board of Supervisors on its 2024 activities and supervisory work, along with the proposed plan for 2025;

Accordingly, the business and production plan for the year 2025 is as follows:

No.	INDICATOR	UNIT	VALUE
I	Industrial Production	Unit of product	513,703,843
1	Plant No. 1	Unit of product	87,055,738
2	Plant No. 2	Unit of product	426,648,105
II	Total Sales Value	VND	299,907,000,113
III	Cost of Goods Sold	VND	223,094,819,228
IV	Total Gross Profit	VND	76,812,180,885
V	Total Selling Expenses	VND	5,009,034,126
	Financial Expenses	VND	3,850,000,000
VI	Administrative Expenses	VND	55,049,459,188
VII	Profit Before Tax	VND	12,903,687,571

Article 2. Approval of the audited financial statements for 2024 (*Pursuant to Proposal No. 01/2025/TTr-DHDCD dated June 30, 2025*).

Article 3. Approval of the selection of an independent auditing firm for the 2025 financial statements (*Pursuant to Proposal No. 02/2025/TTr-DHDCD dated June 30, 2025*).

Article 4. Approval of the profit distribution plan and dividend payout ratio for 2024, and the proposed profit distribution plan and dividend payout ratio for 2025 (*Pursuant to Proposal No. 03/2025/TTr-DHDCD dated June 30, 2025*).

Article 5. Approval of remuneration for the Board of Directors and the Board of Supervisors for 2025 (*Pursuant to Proposal No. 04/2025/TTr-DHDCD dated June 30, 2025*).

Article 6. Approval of the Dismissal for the Additional Members of the Board of Directors for the 2024 – 2029 Term (*Pursuant to Proposal No. 05/2025/TTr-DHDCD dated June 30, 2025*) for Mr. Tran Xuan Dinh, effective from the date on which it is approved by the General Meeting of Shareholders.

Article 7. Approval of the Election for the Additional Members of the Board of Directors for the 2024 – 2029 Term (*Pursuant to Proposal No. 05/2025/TTr-DHDCD dated June 30, 2025*) for:

1. Ms.: Nguyen Ngoc Xuan Trang
2. Ms.: Tran Nguyen Hoang Phuc



This Resolution shall take effect from the date of issuance. The Board of Directors, the Board of Supervisors, the Board of Management, and all relevant departments shall be responsible for implementing this Resolution.

ON BEHALF OF THE 2025 GENERAL MEETING OF SHAREHOLDERS

CHAIRPERSON



Thai Khắc Minh

